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ABSTRACT 
With Fluorescence Resonance Energy Transfer (FRET), we are able to detect 
changes in the structure and affinity of the PLB-SERCA regulatory complex in live cells.  
Using this approach, we have detected a high level of PLB-SERCA interaction even at 
Ca2+ concentrations known to fully relieve PLB inhibition of SERCA, suggesting that 
dissociation is not required for relief of inhibition.  We also detect no real-time change 
in PLB-SERCA binding over the course of a single Ca2+ transient in paced myocytes.  The 
effect of Ca2+ on the PLB-SERCA interaction is best described as a reduced affinity with 
no change in the structure of the complex.  Even though we do not observe a change in 
the structure of the PLB-SERCA complex with changes in calcium concentrations, we 
currently hypothesize that the reduced affinity is produced by a transition of PLB into an 
alternative binding site.  We propose that the transmembrane domain of PLB could 
move independently of its cytosolic domain.  Our fluorescent probe is attached to the 
cytosolic domain of PLB, which would explain our inability to detect a change in the 
position of the transmembrane domain.  My current work attempts to address this by 
measuring the FRET between SERCA and a truncated PLB lacking the cytosolic domain. 
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CHAPTER I INTRODUCTION 
The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) is a responsible for 
maintaining the Ca2+ gradient across the membrane of intracellular vesicles of all cells 
(MacLennan & Kranias, 2003).  This process is of particular importance in muscle cells in 
which Ca2+ triggers contraction by binding troponin C, allowing myosin-actin crossbridge 
formation (Gordon, Homsher, & Regnier, 2000).  SERCA is responsible for decreasing 
cytosolic Ca2+ concentrations necessary for muscle relaxation as well as loading the SR 
with Ca2+ necessary for further release events (Bers, 2008).  SERCA is believed to 
function through a series of coordinated structure changes mediated through the 
binding of Ca2+ and ATP and subsequent hydrolysis of ATP (MacLennan, Toyofuku, & 
Lytton, 1992; Toyoshima & Inesi, 2004).  The two primary generalized structural 
conformations of SERCA are described as the Ca2+ bound state, E1, and Ca2+ unbound 
state, E2.  The continual beating of the heart requires almost constant SERCA activity, 
meaning proper function and regulation is of the utmost importance in the survival of 
the heart. 
In cardiac tissue, phospholamban (PLB) is the primary regulator of SERCA 
activity, and has been shown to bind to and inhibit the activity of SERCA (MacLennan & 
Kranias, 2003).  This inhibition is achieved by decreasing the apparent affinity of Ca2+ for 
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SERCA.  In other words, higher concentrations of Ca2+ are required to the same levels of 
activity that occur in the absence of PLB.  Therefore, Ca2+ can overcome in the inhibition 
of SERCA by PLB, but the mechanism for this relief of inhibition remains unclear.  PLB is 
a key target of β-adrenergic signaling with phosphorylation partially relieving the 
inhibition of SERCA.  Its name is derived from the Greek words for “phosphate” and “to 
receive.” 
A general depiction of Ca2+ handling in cardiac myocytes is depicted in Fig. 1 
(Bers, 2008).  Membrane depolarization causes the opening of L-type Ca2+ channels, 
causing an influx of Ca2+ and resulting in a Ca2+-induced Ca2+ release from the 
sarcoplasmic reticulum (SR) through the ryanodine receptor.  Ca2+ accumulates in the 
cytosol, triggering muscle contraction.  SERCA is responsible for pumping the 
accumulated Ca2+ back into the SR, reducing cytosolic concentrations and loading the SR 
with Ca2+ for future release.  PLB can inhibit SERCA, modulating Ca2+ movement. 
Two basic models have been used to explain the mechanism by which Ca2+ 
overcomes the inhibition by PLB.  For the sake of discussion, I will refer to them as the 
“Dissociation Model” and the “Subunit Model.”   The Dissociation Model suggests that 
PLB stabilizes a structural conformation of SERCA, thereby preventing its transition to an 
alternative conformation capable of binding Ca2+.  Ca2+ essentially competes with PLB 
for binding to SERCA.  Therefore, PLB must be displaced from SERCA for Ca2+ to bind and 
the pumping cycle to proceed.  The Subunit Model suggests that PLB merely slows the  
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Figure 1:  Diagram of the basic calcium handling elements within cardiac myocytes.  
Membrane depolarization opens L-Type calcium channels initiating a calcium induced 
calcium release by the ryanadine receptor (RyR), elevating cytosolic calcium 
concentrations.  This cytosolic calcium is then pumped back into the SR against its 
concentration gradient via SERCA, the activity of which can be inhibited by PLB. 
4 
 
on-rate of Ca2+, allowing the possibility that PLB can remain bound to SERCA throughout 
its reaction cycle.  Both models appear to be incomplete and do not account all data in 
field.  The primary goal of this dissertation is to address these inconsistencies and 
propose an alternative, more inclusive model which we have named the “Domain 
Displacement Model.” 
In this dissertation, I will propose that PLB has an alternative binding site on 
SERCA and that the binding of Ca2+ displaces PLB to this site rather than preventing any 
interaction.  This model is supported through my research as well as evidence from the 
Na, K-ATPase and its regulator phospholemman, a protein system highly homologous to 
PLB-SERCA.  This is also supported by previously published work by our lab showing that 
phosphorylated PLB can still bind SERCA.  This model challenges the general concept 
that relief of inhibition requires dissociation, but is not in conflict with the previous 
research in the field. 
Much of our understanding of SERCA function comes from steady state 
biochemical assays.   However, the contracting heart is by no means a steady state 
environment, especially with respect to Ca2+.  Ca2+ concentration is oscillating on a beat-
to-beat basis facilitating contraction and relaxation.  One of the primary questions of 
this dissertation is how PLB interacts with SERCA over the course of a single Ca2+ 
transient.  Can the elevated Ca2+ from a single transient overcome the PLB inhibition of 
SERCA?  Or can the effect of elevated Ca2+ integrate over time?  
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The biochemical steps of SERCA activity have been well understood since the 
1970’s.  With the more recent detailed structural information coming from 
crystallographic studies, SERCA has provided a unique venue in the study of the 
structure-function relationship of complex proteins.  In this dissertation, I will address 
how PLB is able to interact with various structural conformations of SERCA. 
This dissertation will first start with a review of literature describing SERCA and 
PLB themselves as well our current understanding of the regulatory mechanism.  I will 
then address the conflicting approaches used to assess the PLB-SERCA interaction.   I will 
then discuss how disregulation of SERCA can be involved in disease to underscore the 
importance of this functional interaction. 
In the next section I will discuss the materials and methods employed for this 
dissertation.  This will be followed by a description of an in cell SERCA activity assay 
which we developed to test the functionality of our fusion proteins.  The next section 
addresses the steady-state nature of the PLB-SERCA interaction addressing how PLB 
interacts with SERCA in various conformational steps.  In chapter VI, I show my research 
that directly tests our newly proposed model of PLB-SERCA interaction.  In chapter VII, I 
attempt to show the dynamic nature of the PLB-SERCA interaction by making real-time 
measurements.  Finally, I will discuss the broader implications of my research and how 
my results integrate with the findings of others. 
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I would also like to note that the bulk of work shown in sections IV, V and VII was 
published this past October in the Journal of Biological Chemistry (Bidwell, Blackwell, 
Hou, Zima, & Robia, 2011). 
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CHAPTER II REVIEW OF RELATED LITERATURE 
SERCA 
P-type Ion Pumps 
SERCA belongs to the P-type pump family of ATPases (Kühlbrandt, 2004; 
Wuytack, Raeymaekers, & Missiaen, 2002).   P-type pumps utilize ATP hydrolysis to 
undergo a series of structural transitions, producing a reversibly phosphorylated state, 
from which the family name is derived.  Most family members have 10 transmembrane 
helices (M1-10), though the greatest variation between members occurs in the 
transmembrane region, which determines ion specificity.  
 The family also shares three cytosolic or headpiece domains, the most 
homologous region in the family (Kühlbrandt, 2004; Wuytack et al., 2002).  They are 
commonly called the N, P, and A domains (Nucleotide, Phosphorylation, and Actuator).  
The ATP binding site is located on the N-domain.  A conserved lysine is an integral 
component of the nucleotide binding site.  The gamma-phosphate of that ATP is then 
transferred to an aspartate in a conserved motif, DKTGTLT, on the P-domain.  The P-
domain is also the most highly conserved domain within the family.  The P-domain is 
also homologous to a class of bacterial enzymes demonstrating its general biochemical 
role and importance.  
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SERCA Isoforms 
In vertebrates, 3 distinct genes encode for SERCA that produce at least 10 
different isoforms through alternative splicing (Periasamy & Kalyanasundaram, 2007; 
Wuytack et al., 2002).  SERCA2b is the “housekeeping” isoform found in all cells, at least 
at some low level.  SERCA2a is the predominant isoform found in cardiac muscle and 
slow twitch skeletal muscle.  SERCA1a is expressed in adult fast twitch skeletal muscle 
and has been the most highly studied isoform because of its abundance in and ease of 
collection from animal tissue.  There are 6 SERCA3 isoforms (a-f) found in various 
tissues, with a, d, and f found at low levels in cardiac tissue.  SERCA2a and SERCA1a are 
84% identical with the SERCA3 isoforms being roughly 75% identical to either 
SERCA1a/2a.  Because of the high degree of homology, all SERCA isoforms are believed 
to have almost identical structures.  All isoforms are capable of being inhibited by 
thapsigargin.  SERCA1a and SERCA2a have similar affinities for Ca2+, but SERCA1a has a 
faster catalytic velocity.  SERCA2b has a higher Ca2+ affinity than either SERCA1a/2a, but 
lower catalytic rate. 
Reaction Scheme 
SERCA activity was first observed when isolated SR membrane was shown to 
have ATPase and Ca2+ uptake ability from skeletal muscle (Ebashi & Lipmann, 1962), and 
later from cardiac myocytes (Hasselbach & Makinose, 1962).  Evidence of a 
phosphorylated protein intermediate during the reaction process provides the first 
insight into the mechanism of SERCA function.  In 1966, Jardetzkey postulated the 
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simple but still accepted model of ion transport where ions bind with differential affinity 
on opposing sides of the membrane (high on the binding or uptake side and low on the 
release or discharge side).  This is coupled to a phosphorylation dependent 
conformational change closing the binding pocket on one side and opening it on the 
other (Jardetzky, 1966).  Landgraf and Inesi were the first to demonstrate a 
conformational change of SR protein in response to ATP through EPR spin labeling 
(Landgraf & Inesi, 1969).  Tanford further proposed that the change in binding pockets 
and affinities could occur simultaneously through a simple movement of membrane 
helices altering amino acid side chain interactions  that facilitate ion interaction 
(Tanford, 1982).  
 In 1970, Inesi first described a hallmark of SERCA activity, the dependence of 
Ca2+ on the rate of ATPase activity.  At low concentrations where little Ca2+ is available 
to be pumped across the membrane, SERCA activity is low.  Increasing Ca2+ increases 
SERCA activity up to maximal level.  Along with Inesi, many other groups begin to 
characterize the stepwise reaction scheme describing the SERCA reaction cycle 
(Carvalho, de Souza, & de Meis, 1976; Coan & Inesi, 1976; Hasselbach, 1978; Kanazawa 
& Boyer, 1973; de Meis & Vianna, 1979), on which a general consensus is reached by 
1979, as depicted in Fig. 2.  All steps were shown to be reversible, providing the 
possibility of ATP production. These concepts are still accepted today.  A Ca2+ to ATP  
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Figure 2: Simplified SERCA reaction diagram.  One ATP and two Ca2+ ions bind on the 
cytosolic face of the E1 conformation of SERCA, which initiates ATP hydrolysis and 
phosphate transfer.  The phosphorylated SERCA then readily transitions to the E2 
conformation, changing the Ca2+ binding sites from high affinity and cytosolic facing to 
low affinity and lumen facing.  Ca2+ is then released to the ER/SR lumen, along with the 
release of ADP and PI, producing the free E2 conformation. 
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stoichiometry of 2:1 was first proposed in 1963 (Hasselbach & Makinose, 1963), but not  
clearly described until 1980 (Inesi, Kurzmack, Coan, & Lewis, 1980).  In the same study,  
Inesi et al also demonstrate the cooperative binding of Ca2+.  Spin labeling detected a 
structure change after binding of the first Ca2+ ion which is presumed to increase the 
binding affinity of the second ion.  
SERCA Structure 
 SERCA was first isolated from rabbit skeletal muscle in 1970 (MacLennan, 1970).  
Structural information first came from proteolysis analyses where trypsin digestion of 
SERCA produced various fragments and subfragments.  ATP and Ca2+ binding could be 
associated with these specific fragments.  In 1980, partial amino acid sequences were 
determined for the cytosolic fragments (Allen, Trinnaman, & Green, 1980).  In 1985, 
SERCA1a was cloned for the first complete sequence (MacLennan, Brandl, Korczak, & 
Green, 1985).  The following year SERCA2a was cloned and sequenced (Brandl, Green, 
Korczak, & MacLennan, 1986).  From these sequences, the MacLennan group deduced 
the topology and secondary structure of SERCA, predicting the helical transmembrane 
domains and the globular cytosolic domains. 
 SERCA was first visualized with electron microscopy identifying 40 Å diameter 
surface particles on skeletal muscle microsomes (Martonosi, 1968), and later identified 
by freeze fracture (Baskin & Deamer, 1969; Deamer & Baskin, 1969).  The first low 
resolution crystal structure from X-ray diffraction (14 Å) showed a large cytosolic 
headpiece attached to a narrow transmembrane region (Toyoshima, Sasabe, & Stokes, 
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1993).  With enhancement of the resolution to 8 Å, the 10 transmembrane helices could 
be visualized and could be associated to the appropriate primary structure sequence 
(Zhang, Toyoshima, Yonekura, Green, & Stokes, 1998).  After developing conditions 
sufficient to grow crystals suitable for X-ray diffraction, a high resolution (2.6 Å) 
structure was determined capable of resolving the 3 cytosolic domains (Toyoshima, 
Nakasako, Nomura, & Ogawa, 2000).  High resolution structures have subsequently 
been determined under a variety of conditions and have been associated with 
intermediate conformations of SERCA (Toyoshima & Inesi, 2004; Toyoshima & Nomura, 
2002).  Fig. 3 depicts a few of the proposed intermediate conformations showing 
potential large movements of the cytosolic headpiece. 
Structure Function Relationship 
Integrating the enzymatic and structural data has been a fundamental goal 
within the field.  After cloning SERCA, the MacLennan lab performed extensive 
mutagenesis studies investigating the role of individual residues (MacLennan, 1990).  
Many loss-of-function mutants retained the capability of undergoing partial reactions, 
enabling investigation into the particular steps affected by alteration of these residues.  
This approach clearly identified Asp351 as the site of phosphoryl transfer (Maruyama et 
al., 1989). This approach also lead to the preliminary identification of the Ca2+ binding 
sites in the transmembrane region (Clarke et al., 1989; Vilsen, Andersen, Clarke, & 
MacLennan, 1989) and of the ATP binding site (Clarke, Loo, & MacLennan, 1990).  These 
binding sites have been subsequently confirmed by high resolution X-ray crystallography  
13 
 
 
 
 
Figure 3: Proposed SERCA structural transitions.  SERCA is believed to undergo 
conformational transitions upon binding of calcium and ATP, potentially producing large 
movements of the cytosolic headpiece.  Images represent various crystal structures 
produced under conditions thought to be associated with reaction step intermediates. 
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(Toyoshima & Inesi, 2004; Toyoshima & Nomura, 2002; Toyoshima et al., 2000).  These 
studies demonstrate that ATP binding and hydrolysis occur in the cytosolic headpiece far 
from the Ca2+ binding sites in the transmembrane region.  Therefore the 
transmembrane reorientation necessary for Ca2+ transport is linked to the required 
chemical energy through long-range protein interactions. 
The various high resolution crystal structures have shown many distinct 
conformations of SERCA (Toyoshima & Inesi, 2004; Toyoshima & Nomura, 2002; 
Toyoshima et al., 2000).  The conditions under which these crystals were produced can 
be associated with endpoints of the enzymatic half reactions.  Therefore, these 
conformations are thought to correspond to the various enzymatic states of the SERCA 
reaction cycle (Fig. 3).  Initial results suggested that the stepwise binding of Ca2+ and ATP 
induce large scale conformational changes in the cytosolic headpiece domains.  These 
conformational shifts in the headpiece were thought to produce the mechanical force 
necessary to rearrange the transmembrane helices shifting the orientation of the Ca2+ 
binding sites.  However, more recent crystal structures suggest that the structural 
changes are much smaller and more subtle than previously believed (Jensen, Sørensen, 
Olesen, Møller, & Nissen, 2006; Sørensen, Møller, & Nissen, 2004).  This concept of 
smaller structural movements is also supported by FRET distance measurements 
between probes attached to different cytosolic domains (Winters, Autry, Svensson, & 
Thomas, 2008). 
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Phospholamban 
Discovery 
 The existence of PLB was first observed with the PKA dependent stimulation of 
the ATPase dependent Ca2+ uptake in cardiac SR vesicles (Kirchberger, Tada, Repke, & 
Katz, 1972; Tada, Kirchberger, Repke, & Katz, 1974).  These vesicles were then shown to 
be radiolabeled by P32 upon stimulation by PKA (Kirchberger, Tada, & Katz, 1974).  This 
radiolabeling was found to be targeted to a 22 kDa protein which was shown to be a 
modulator of SERCA (Tada, Kirchberger, & Katz, 1975).  This phosphoprotein was 
subsequently termed phospholamban coming from the Greek terms “to receive” and 
“phosphate” (Kirchberger, Tada, & Katz, 1975).   
This 22 kDa protein was shown to be capable of dissociating into lower 
molecular weight components upon boiling or treatment with Triton-X (Jones, Besch, 
Fleming, & Mcconnaughey, 1979; Lamers & Stinis, 1980; Le Peuch, Haiech, & Demaille, 
1979; Will, Levchenko, Levitsky, Smirnov, & Wollenberger, 1978).  Freezing of the 
sample was shown to cause reassociation of the lower-molecular weight forms back to 
the 22 kDa.  These observations suggested that phospholamban could exist as an 
oligomer.  The lower molecular form was eventually determined to be a 6 kDa peptide 
that could be independently phosphorylated by PKA (Bidlack & Shamoo, 1980; Bidlack, 
Ambudkar, & Shamoo, 1982).  After improved purification techniques, the high 
molecular weight form was shown to be a  30 kDa pentamer of composed of 
indistinguishable monomers which could each be independently phosphorylated (Fujii, 
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Kadoma, Tada, Toda, & Sakiyama, 1986; Wegener & Jones, 1984; Wegener, Simmerman, 
Liepnieks, & Jones, 1986).  The full sequence of PLB was determined after it was cloned 
by the Tada lab (Fujii et al., 1987). 
Structure 
 PLB is a 52 amino acid integral membrane protein that is comprised of 3 
domains, Ia (residues 1-20), Ib (residues 21-30), and II (residues 31-52) (Bhupathy, Babu, 
& Periasamy, 2007).  Proteolysis studies first suggested the existence of 2 domains, a 
protease sensitive cytosolic domain (1a/b) and protease insensitive transmembrane 
domain (II) (Wegener et al., 1986).  Circular dichroism experiments further suggested 
the existence a cytosolic (Ia) and transmembrane (II) alpha helices separated by and 
unstructured linker or hinge domain (1b) (Simmerman, Lovelace, & Jones, 1989; Terzi, 
Poteur, & Trifilieff, 1992).  These observations were consistent with sequence analysis 
proposing likely alpha helical and hydrophobic/hydrophilic regions (Fujii et al., 1986, 
1987).  These observations are also consistent with NMR structures of PLB (Traaseth et 
al., 2009) and molecular dynamics simulations (Paterlini & Thomas, 2005). 
A fundamental aspect of phospholamban is that it can exist in a monomer as 
well as a pentamer (MacLennan & Kranias, 2003; Simmerman & Jones, 1998).  The alpha 
helical structure of the PLB transmembrane region generates heptad repeats.  Because 
this pattern, every 3 to 4 residues of the helix align, organizing leucines and isoleucines 
along one side or face PLB.  Mutagenesis targeting these residues destabilized pentamer 
formation whereas mutations along the opposite face of PLB did not alter pentamer 
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stability.  This suggests that the leucine zipper formation found within the PLB structure 
is critical for pentamer assembly (Simmerman, Kobayashi, Autry, & Jones, 1996).  This 
conclusion has been supported by subsequent NMR studies (Verardi, Shi, Traaseth, 
Walsh, & Veglia, 2011).  Mutations at 3 cysteines within the transmembrane domain 
(residues 36, 41, and 46) have been shown to destabilize PLB pentamer formation (Fujii, 
Maruyama, Tada, & MacLennan, 1989), but disulfide linkages were not observed and 
are believed be unnecessary for pentamer stability (C. B. Karim, Stamm, Karim, Jones, & 
Thomas, 1998; Simmerman, Collins, Theibert, Wegener, & Jones, 1986).  Replacement of 
cysteines with an isosteric amino acid (α-amin-n-butyric) was shown to have no affect 
on pentamer stability (C. B. Karim et al., 2001).  This demonstrates that the steric 
properties of the cysteines, not their reactivity, contribute pentamer stability. 
Because PLB can exist as a pentamer, monomer, and monomer bound to SERCA, 
PLB exists in a coupled equilibrium depicted in Fig. 4.  This concept was first 
demonstrated when mutations that make PLB more monomeric were shown have 
enhanced inhibitory potential and are considered “superinhibitors” (Y Kimura, Asahi, 
Kurzydlowski, Tada, & MacLennan, 1998; Y Kimura, Kurzydlowski, Tada, & MacLennan, 
1997).  These observations are also consistent with work in our lab showing that a 
superinhibitory PLB mutant enhances FRET between PLB and SERCA while diminishing 
PLB pentamer FRET to an equivalent degree (Kelly, Hou, Bossuyt, Bers, & Robia, 2008).  
These studies suggest that themonomer is the active inhibitor of the pump, with the 
pentamer being an inactive reservoir, incapable of interacting with SERCA.  Through 
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Figure 4: Coupled equilibrium of PLB binding.  PLB can exist as a pentamer, free 
monomer, and monomer bound to SERCA.  PLB readily transitions between pentamer 
and free monomer (KD1) and between free monomer and monomer bound to SERCA 
(KD2).  Therefore changes in pentamer binding will alter the binding of PLB to SERCA. 
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mass action, changes in pentamer binding will alter binding between PLB and SERCA, 
thereby altering the ability of PLB to inhibit SERCA.   
X-ray crystal studies have suggested the possibility that the pentamer could 
directly interact with SERCA (Stokes, Pomfret, Rice, Glaves, & Young, 2006).  However, 
this inconsistent with studies from our lab showing a 1:1 stoichiometry in PLB-SERCA 
FRET (Kelly et al., 2008).  Because this interaction could be an artifact of crystallization, 
further study is needed for its validation.  
Phosphorylation 
 PLB is the target of β-adrenergic signaling through PKA phosphorylation of Ser16 
and CamKII phosphorylation of Thr17 (Fujii et al., 1989; Simmerman et al., 1986).  Thr17 
has also been shown be phosphorylated independently of Ser16 in a frequency 
dependent manner likely through enhanced CamKII activity (Hagemann et al., 2000; 
Mundiña-Weilenmann, Vittone, Ortale, de Cingolani, & Mattiazzi, 1996).  
Phosphorylation of Ser16 and Thr17 can occur independently in vitro (Davis, Schwartz, 
Samaha, & Kranias, 1983; Jackson & Colyer, 1996; Kranias, 1985).  However, during in 
vivo studies, phosphorylation of Ser16 appears to be a prerequisite for phosphorylation 
of Thr17 through the β-adrenergic pathway (Chu et al., 2000; Luo et al., 1998).  Protein 
phosphatase-1 (PP1) has been shown to dephosporylate PLB at both sites which 
decreases SERCA activity (Kranias & Di Salvo, 1986; MacDougall, Jones, & Cohen, 1991; 
Nicolaou, Hajjar, & Kranias, 2009). 
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These phosphorylations can independently relieve PLB inhibition of SERCA 
thereby enhancing its activity by restoring the Ca2+ sensitivity of SERCA (MacLennan & 
Kranias, 2003).  In some early studies, it was suggested that the Ser16 and Thr17 
phosphorylations have an additive effect on SERCA activity (Kranias, 1985; Le Peuch et 
al., 1979; Raeymaekers, Hofmann, & Casteels, 1988), but these studies do not directly 
assess phosphorylation efficiency of their experimental conditions.  Further studies 
demonstrating full phosphorylation show no additive effect suggesting that the 
previously observed additive effect may have been due to incomplete phosphorylation 
of PLB (Colyer & Wang, 1991; Jackson & Colyer, 1996).   
Mechanism of PLB Inhibition of SERCA 
SERCA activity increases with Ca2+ concentration up to a maximum level with a 
Hill function relationship (Fig. 5, black).  PLB is known to reduce the apparent Ca2+ 
affinity of SERCA, producing a rightward shift in the SERCA activity curve (Fig. 5, red).  
Higher Ca2+ concentrations are then needed to achieve the same levels of activity 
observed in the absence of PLB.  In other words, increases in Ca2+ concentration can 
overcome the inhibition by PLB.  Phosphorylation of PLB relieves the inhibition on SERCA 
by partially restoring Ca2+ sensitivity, represented as a leftward shift in the SERCA 
activity curve (Fig. 5, blue).  The process of this relief of inhibition is not fully understood 
and is the focus of this dissertation.   
SERCA is believed to exist in various conformational states.  Early evidence 
comes from protein digestion studies, where changes in tertiary structure block or allow 
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Figure 5: Simulated example of SERCA activity assay.  SERCA activity, which can be 
measured by ATPase activity or calcium uptake, increases with increasing cytosolic 
calcium concentration in a sigmoidal manner up to a maximal level (black).  The 
presence of PLB causes a decreased apparent calcium affinity represented by a 
rightward shift in the activity curve (red).  Higher cytosolic calcium concentrations are 
needed to achieve the same SERCA activity.  Phosphorylation of PLB shifts this curve 
back to left (blue). 
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 access to cut sites.  This approach identified 2 primary SERCA conformations: the E1 
Ca2+ bound state and the E2 Ca2+ unbound state.  More recent X-ray structures have 
been determined for SERCA under various conditions, corresponding to more 
conformational states.  These conformational states are believed to correspond to 
reaction cycle intermediates. 
Dissociation Model 
The prevailing view favors a model where PLB binds the E2 Ca2+ free state of 
SERCA.  Interaction with PLB stabilizes this conformation thereby blocking transition to 
the E1 conformation by increasing the free energy barrier.  Inability to transition to a 
conformation capable of binding Ca2+ terminates the reaction cycle of SERCA.  PLB must 
then completely dissociate from SERCA for transition to occur and activity to be 
restored.  In this model, binding of PLB and Ca2+ to SERCA is mutually exclusive.  I will 
refer to this model as the “Dissociation Model” which is depicted in Fig. 6A. 
The Dissociation Model is well supported by chemical crosslinking studies from 
Jones group.  In an initial study, a mutant which introduced a Cys at residue 30 of PLB 
(N30C) was coexpressed in insect vesicles (Jones, Cornea, & Chen, 2002).  Addition of a 
homobifunctional thiol probe, bismaleimidohexane, was shown to chemically crosslink 
the introduced Cys of N30C to Cys318 of canine SERCA2a.  This demonstrated that 
residue 30 of PLB was in close proximity to residue 318 of SERCA.  This chemical 
crosslinkage could be disrupted through increases in Ca2+ concentration, exhibiting an 
EC50 of 130 nM.  At high Ca
2+ concentrations, crosslinking was completely abolished.   
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Figure 6: Models of PLB inhibition of SERCA.  (A) The Dissociation Model suggests that 
PLB selectively binds the E2 calcium unbound state of SERCA preventing transition to 
the E1 conformation capable of binding calcium.  PLB must then completely dissociate 
from SERCA for function to be restored.  (B) The Subunit Model suggests that PLB binds 
all conformations of SERCA, and merely slows the binding of calcium and transition to 
the E1 conformation.  Evidence for both models stems from assessment of the ability to 
bind the E1 conformation (orange boxes), produced by high calcium conditions, with 
different methods favoring different models. 
 
A B 
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Further studies using a similar approach showed that residue 27 of PLB was in 
close proximity to residue 328 of SERCA, and that residues 45-52 of PLB were in close 
proximity to residue 89 of SERCA.  Crosslinking at these sites was also completely 
abolished by increases in Ca2+ concentration, with EC50 values ranging from 100 to 900 
nM (Chen, Akin, Stokes, & Jones, 2006; Chen, Stokes, & Jones, 2005).   
In a recent study, the Jones group has generated a method to crosslink 
endogenous PLB and SERCA2a from isolated human cardiac tissue, generating results 
consistent with their previous studies (Akin, Jones, 2012).  This is an advancement over 
previous studies since measurements are made with endogenously expressed proteins 
in the most physiologically relevant membrane environment.  Any accessory and/or 
anchoring proteins would also be intact within this system.  Also, neither protein has 
crosslinking sites introduced through a mutation that could alter proper function and 
interaction. 
These studies show the disruption of PLB-SERCA binding at multiple points of 
contact by elevated Ca2+ concentrations.  While some residual level of crosslinking (5% 
of control) can be observed even at saturating concentrations, the Jones group states 
Ca2+ completely abolishes crosslinking.  The Jones group then concludes that PLB is able 
to compete with Ca2+ for its binding site on SERCA, and that complete dissociation of 
PLB and SERCA is required for restoration of SERCA activity. 
Their approach and conclusions are supported by additional studies exploring 
the effects of PLB phosphorylation on PLB-SERCA crosslinking.  Much like elevated Ca2+ 
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concentration, phosphorylation of PLB is known to overcome SERCA inhibition by PLB.  
Also like elevated Ca2+, they demonstrated that PKA phosphorylation of PLB prevented 
crosslinking between PLB and SERCA (Chen, Akin, & Jones, 2007).  This further supports 
their previous conclusion that relief of PLB inhibition is accomplished through the 
unbinding of PLB from SERCA. 
The Dissociation Model is also supported by immunoprecipitation studies by the 
MacLennan group.  They first demonstrated that inhibitory ability of various mutants 
(loss and gain of function) correlates with their ability to co-immunoprecipitate with 
SERCA (Asahi, Kimura, Kurzydlowski, Tada, & MacLennan, 1999).  Subsequently, they 
demonstrated that Ca2+ can also disrupt the ability of PLB to co-immunoprecipitate with 
SERCA (Asahi, McKenna, Kurzydlowski, Tada, & MacLennan, 2000).  These studies 
demonstrate that relief of inhibition correlates to loss of PLB-SERCA interaction, in 
support of the Jones group conclusions. 
Despite the clear and well characterized results of the crosslinking and 
immunoprecipitation assays, the approaches and subsequent conclusions have 
limitations.  While the crosslinking assay is highly sensitive and specific, the close 
proximity of targeted residues on PLB and SERCA are only assessed.  Even subtle 
changes in the position and/or orientation of PLB in relation to SERCA could prevent the 
crosslinking.  Small rotations in the transmembrane helices of SERCA could prevent 
access of the chemical crosslinkers to the target residues.  These factors demonstrate 
how crosslinking could be abolished without significant dissociation of the PLB-SERCA 
26 
 
complex.  Furthermore, even at saturating Ca2+ concentrations, a low level of 
crosslinking is observed in many cases.  This observation is not in agreement with 
complete dissociation.  
Despite agreement between crosslinking and immunoprecipitation on the effect 
of Ca2+ on the PLB-SERCA interaction, the observations from these approaches differ 
under other conditions.  A SERCA ligand, thapsigargin, as well as phosphorylation of PLB 
have been shown to block the PLB-SERCA crosslinking (Chen et al., 2006, 2005), but 
neither affects PLB-SERCA co-immunoprecipitation (Asahi et al., 2000).   
The largest complication with immunoprecipitation is that the membrane is 
perturbed by detergents prior to the detection of the interaction between PLB and 
SERCA.  Immunoprecipitation between membrane bound proteins like PLB and SERCA 
will be highly susceptible to variations in experimental conditions.  Furthermore, 
antibodies targeted to PLB, such as those used to pull down the PLB-SERCA complex in 
the co-immunoprecipitation experiments, have themselves been shown to block PLB-
SERCA crosslinking (Chen et al., 2007) and relieve PLB inhibition of SERCA (Cantilina, 
Sagara, Inesi, & Jones, 1993; Y Kimura et al., 1991; Morris, Cheng, Colyer, & Wang, 1991; 
Sham, Jones, & Morad, 1991).  These factors may explain the inconsistent results 
between the two approaches.  These factors also argue why immunoprecipitation may 
not be an effective strategy to investigate PLB-SERCA binding and therefore may not 
lend the crosslinking studies sufficient corroborating support. 
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 The Dissociation Model is described by the competitive binding of PLB and Ca2+ 
for SERCA.  In competitive inhibition, Ca2+ binding (activity) can always be overcome by 
further increases in the concentration of inhibitor.  However, this is inconsistent with 
studies measuring the dose response of PLB.  The maximal inhibition of SERCA, indicated 
by decreased apparent Ca2+ affinity, is achieved by a 2.6 fold increase of PLB expression 
(Brittsan, Carr, Schmidt, & Kranias, 2000).  Further overexpression of PLB does not 
enhance the inhibition of SERCA, as would be predicted if PLB competed with Ca2+.   
Furthermore, crosslinking is never completely abolished even at saturating 
concentrations inconsistent with the Jones group conclusions and the concept of 
competitive inhibition. 
Subunit Model 
 In contrast to the Dissociation Model, the Subunit Model has been proposed 
suggesting that PLB can remain bound to SERCA throughout its reaction cycle as 
depicted in Fig. 6B.  The decrease in apparent Ca2+ affinity is achieved by slowing a rate 
limiting step of the reaction cycle, likely the on-rate of Ca2+.  This is consistent with the 
observation that high Ca2+ can overcome inhibition by PLB.   
 Support for this model first comes from a study showing that a PLB antibody 
enhances Ca2+ transport by SERCA in isolated cardiac vesicles (Cantilina et al., 1993).  
This antibody produces an increased formation of the autophosphorylated SERCA 
intermediate (E1-P) as would be expected with increased activity and turnover of the 
pump.  However, this antibody was unable to alter the Ca2+ binding in the absence of 
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ATP at equilibrium.   This suggests that SERCA inhibition by PLB is not achieved by 
lowering the actual affinity of Ca2+ for the pump.  The decrease in apparent Ca2+ affinity 
in the presence of PLB is then achieved by a decreased turnover of the SERCA pump.  
Decreased turnover is explained by a slowed transition from the E2 to E1 conformations 
produced by a slower Ca2+ on-rate.  
These equilibrium binding experiments were performed in the absence of ATP, 
which has been viewed as a flaw.  Since ATP is a critical and necessary for SERCA 
function, it could then alter the Ca2+ affinity and control how PLB might affect this 
equilibrium.  The conclusion that PLB decreases the on-rate of Ca2+ has then been 
disputed on this assertion (Jones et al., 2002).  However, no study has described 
equilibrium Ca2+ binding in the presence of ATP in the nearly 20 years since Cantilina et 
al was published.  This is likely due to the complexity of this seemingly simple 
experiment.  The presence both Ca2+ and ATP will induce SERCA cycling and Ca2+ 
transport, thereby preventing equilibrium from being achieved.   
 Equilibrium Ca2+ binding experiments have also been performed in using purified 
proteins in a reconstituted membrane (Hughes, Starling, Sharma, East, & Lee, 1996).  
Consistent with Cantilina et al, the results show no effect of PLB on Ca2+ binding at 
equilibrium.  However, in contrast to Cantilina et al, this study shows no change in the 
rate of the SERCA auto-phosphorylation, and suggests that PLB disrupts the off-rate of 
Ca2+. 
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 The Subunit Model is also supported by a study measuring FRET between PLB 
and SERCA  (Mueller, Karim, Negrashov, Kutchai, & Thomas, 2004).  High levels of 
energy transfer were detected between purified, fluorescently-labeled PLB and SERCA in 
a reconstituted membrane, even at saturating Ca2+ concentrations.  A small but 
significant increase in the distance between the fluorescent probes was detected by the 
elevation of Ca2+ concentration.  This suggests that relief of inhibition occurs through a 
structural rearrangement in the PLB-SERCA complex, rather than from complete 
dissociation of PLB from SERCA.   
 One criticism of this study was the use of purified protein in a reconstituted 
membrane.  Being in such a non-physiological system could disrupt proper interaction 
between PLB and SERCA, thereby producing anomalous results.  The membrane 
composition and high relative concentration of protein could produce nonspecific 
binding.  Also, the fluorescent probes themselves could induce aggregation of PLB and 
SERCA.  However, this argument neglects that the distance estimations between PLB 
and SERCA are consistent with the predicted binding location.  Furthermore, activity 
assays demonstrate that elevated Ca2+ can overcome PLB inhibition in this system.  
Since functional regulation occurs, it suggests that the PLB-SERCA binding detected are 
specific and not anomalous.  Also, if the fluorescent probes were inducing nonspecific 
aggregation, this would reduce the ability of PLB to regulate SERCA, which is not 
observed.  Labeled and unlabeled PLB inhibit SERCA activity to the same degree. 
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Structure-Function Relationship of PLB inhibition 
 PLB is only expressed in cells expressing SERCA2a and not in cells expressing 
SERCA1a (MacLennan & Kranias, 2003; Tada & Toyofuku, 1998).  However, the 
interaction between PLB and SERCA1a has been extensively studied despite not being 
physiological binding partners.  This interaction has been studied due to the wealth of 
structural information of SERCA1a and the suspected high degree of structural and 
functional similarities between the two isoforms (Asahi et al., 1999; Kühlbrandt, 2004; 
Morth et al., 2007).  Furthermore, PLB has been shown to inhibit SERCA1a and SERCA2a 
to the same extent (Toyofuku, Kurzydlowski, Tada, & MacLennan, 1993).  PLB also shows 
the ability to crosslink both isoforms in a similar manner (Chen et al., 2006, 2005; Jones 
et al., 2002; Toyoshima et al., 2003).  The study of the PLB-SERCA1a therefore aids in the 
better modeling of the PLB-SERCA interaction.  Despite these extensive similarities, our 
lab has shown that PLB has a higher affinity for SERCA1a compared to SERCA2a (Hou & 
Robia, 2010).  While this observation does not discount the other similarities, it is an 
important consideration when interpreting the results from SERCA1a. 
The hallmark of PLB inhibition of SERCA is a reduced apparent affinity of Ca2+ 
(increased KCa as in Fig. 5) which is generally thought to occur through transmembrane 
interactions of the two proteins (MacLennan & Kranias, 2003).  This concept is 
supported by studies showing that a truncated PLB lacking the cytosolic domain was 
capable of reducing Ca2+ sensitivity of SERCA to the same degree as full length PLB 
(Hughes et al., 1996; Y Kimura, Kurzydlowski, Tada, & MacLennan, 1996).  Evidence for 
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the role of transmembrane interactions also comes from a homolog of PLB, sarcolipin 
(SLN).  The transmembrane regions of PLB and SLN have a high degree of similarity, but 
SLN lacks a comparable cytosolic domain ( a Odermatt et al., 1997). Despite the lack of 
cytosolic domain, SLN displays the ability to reduce the apparent affinity for Ca2+ of 
SERCA like PLB (MacLennan, Asahi, & Tupling, 2003;  a Odermatt et al., 1998). 
While the role of the transmembrane region in the inhibition of SERCA is well 
described, the role of the cytosolic domain of PLB is less understood.  PLB can inhibit 
both SERCA1a and SERCA2a, but is unable to inhibit SERCA3 (Kimura et al., 1996).  
However, a truncated PLB lacking the cytosolic domain is able to inhibit SERCA3 
indicating a critical role for the cytosolic domain.  A region in the nucleotide binding 
domain of SERCA3 was identified that prevented regulation by PLB (Toyofuku et al., 
1993; Toyofuku, Kurzydlowski, Tada, & MacLennan, 1994).  Specifically, when the 
SERCA3 sequence of Gln-Gly-Glu-Gln-Leu401 was converted to the corresponding 
SERCA2a sequence of Lys– Asp–Asp–Lys–Pro401, SERCA3 gained the ability to be 
regulated by PLB.  However, a specific role for this sequence has not been determined, 
but these findings point to at least some regulatory role of the PLB cytosolic domain that 
does not directly confer inhibition.   
A direct inhibitory function of the cytosolic domain has been suggested and 
investigated, though the findings have not been consistent.  Many studies have 
examined the potential effect in isolated cardiac vesicles.  Early studies suggested that 
phosphorylation of the cytosolic domain of PLB could enhance the maximal catalytic 
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rate (Vmax) of SERCA in isolated cardiac SR vesicles (Adunyah, Jones, & Dean, 1988).  
However, later studies disputed these findings showing that phosphorylation of PLB had 
no effect on Vmax in isolated cardiac vesicles ( a Mattiazzi, Hove-Madsen, & Bers, 1994; 
M A Movsesian, 1992; Matthew A Movsesian, Colyer, Wang, & Krall, 1990).  An isolated 
peptide corresponding to the PLB cytosolic domain (residues 1-31) was shown to 
decrease the Vmax of SERCA with no impact on Ca
2+ affinity (Sasaki, Inui, Kimura, Kuzuya, 
& Tada, 1992).  These results were supported by studies showing that the removal of 
the PLB cytosolic domain through tryptic digestion (Lu & Kirchberger, 1994; Lu, Xu, & 
Kirchberger, 1993) caused an increase in the Vmax of SERCA in isolated cardiac vesicles.   
Exposure of an antibody targeted to the cytosolic domain of PLB to isolated vesicles was 
shown to decrease Vmax in one study (Antipenko, Spielman, Sassaroli, & Kirchberger, 
1997) while having no effect on Vmax in another (Cantilina et al., 1993).  Variations in 
vesicle preparation were shown to impact detection of a Vmax change potentially 
explaining the differing results (Antipenko, Spielman, & Kirchberger, 1999).  
Rather than using isolated vesicles, many labs studied the role of the cytosolic 
domain by expressing PLB an SERCA in heterologous cells or reconstituted them in a 
purified membrane.  When SERCA was reconstituted into a membrane with and without 
PLB, the expected change in KCa was observed with no change in the Vmax parameter 
(Reddy et al., 1995; Reddy, Jones, Pace, & Stokes, 1996).  These studies also observed no 
change in SERCA activity in response to the isolated peptide corresponding to residues 
1-31 of PLB.  These studies were also supported by an analogous study expressing PLB 
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and SERCA in HEK cells also showing no change in the Vmax parameter (A. Odermatt, 
Kurzydlowski, & MacLennan, 1996).  These studies have been disputed by another group 
showing that the isolated PLB cytosolic domain can decrease Vmax in a reconstituted 
system and that a truncation of PLB removing the cytosolic domain increases Vmax 
(Hughes, East, & Lee, 1994; Hughes et al., 1996; A. P. Starling, Hughes, Sharma, East, & 
Lee, 1995).  They also demonstrate that experimental conditions used to reconstitute 
PLB and SERCA have an effect on the observation of a Vmax change (A. P. Starling et al., 
1995), much like Antipenko et al describes with vesicle preparations (Antipenko et al., 
1999). 
While phosphorylation of PLB is known to favor pentamer formation, mass 
action equilibrium binding changes may not fully explain the relief of PLB inhibition 
through phosphorylation.  Phosphorylation of PLB has been shown to prevent chemical 
crosslinking to SERCA (Chen et al., 2007), which is in agreement with the idea of mass 
action changes.  However, our lab has shown using FRET that phosphomimetic mutants 
of PLB can interact with SERCA, though with a diminished affinity and altered structure 
compared to wild-type PLB (Hou, Kelly, & Robia, 2008).  This structure change in the 
regulatory complex might also be linked to relief of inhibition.  EPR amd NMR studies 
have been used to show that phosphorylation of PLB introduces disorder into the alpha-
helix of the cytosolic domain (Metcalfe, Traaseth, & Veglia, 2005) and that this 
phosphorylation does not alter the affinity of the transmembrane domain for SERCA 
(Traaseth, Thomas, & Veglia, 2006).  To explain the PLB-SERCA inhibitory mechanism as 
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well as the effect of phosphorylation on this mechanism, the Veglia group proposes an 
allosteric model of PLB interaction (Traaseth et al., 2006; Zamoon, Nitu, Karim, Thomas, 
& Veglia, 2005).   They propose that PLB is in equilibrium between two states, an 
ordered T state and a disordered R state.  In both states, the transmembrane domain of 
PLB is capable of interacting with SERCA, but only the T state can inhibit SERCA.  
Unphosphorylated PLB favors the order T state and is therefore inhibitory, while 
phosphorylated PLB favors the disordered R state and is unable to inhibit. 
Predicted PLB Binding Location 
 A structure of a co-crystal between SERCA1a and PLB monomer has been 
determined using cryo-electron microscopy, though not to sufficient resolution to 
determine the binding location of PLB (H. S. Young, Jones, & Stokes, 2001).  Scanning 
alanine mutagenesis of SERCA1a indentified several residues on helix M6 critical for PLB 
inhibition suggesting that this helix is a likely point of contact (M Asahi et al., 1999).  This 
observation was consistent with later molecular modeling positioning the 
transmembrane domain of PLB in close proximity to helix M6 (Hutter et al., 2002).  
Using distance constraints from PLB-SERCA crosslinking studies, subsequent modeling 
predicts that the transmembrane domain of PLB is positioned in a groove comprised of 
helices M2, M4, and M6 of SERCA (Fig. 7A) (Toyoshima et al., 2003).  This study utilized 
crosslinking results from both SERCA1 and SERCA2a since the distance constraints were 
compatible.  The consistency in the crosslinking studies also demonstrates that PLB 
likely interacts with SERCA1a and SERCA2a in a similar manner. 
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Figure 7: Predicted regulator binding locations.  (A) Crosslinking studies predict PLB (red) 
to interact with SERCA in a binding pocket described by helices M2, M4, and M6 (blue).  
(B) Co-crystalization has provided evidence of that PLM (red) interacts with NKA with a 
more exterior helix M9 (green). 
A B 
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 While the positioning of the transmembrane domain of PLB in relation to SERCA 
is well supported, less is known about the binding location of the cytosolic domain.  
Initial crosslinking studies predicted that Lys3 of PLB interacts with either Lys397 or Lys400  
of SERCA (James, Inui, Tada, Chiesi, & Carafoli, 1989).  This observation is supported by a 
study showing that the sequence Lys– Asp–Asp–Lys–Pro–Val402 in SERCA is critical for 
PLB regulation (Toyofuku et al., 1994).  These results have been used to model the 
position of the cytosolic domain.  However, subsequent crosslinking studies have been 
unable to provide corroborating evidence calling the initial study into question (Chen, 
Stokes, Rice, & Jones, 2003). 
 Insights into the PLB-SERCA regulatory complex structure may also come from 
homologous proteins, Na, K-ATPase (NKA) and phospholemman (PLM).  NKA is a P-type 
ion pump like SERCA and is thought to function in a similar manner (Kühlbrandt, 2004; 
Wuytack et al., 2002).  The X-ray crystal structure of NKA shares a high degree of 
resemblance to that of SERCA (Morth et al., 2007) further supporting their potential 
functional similarities.  PLB and PLM are structurally homologous having a single 
transmembrane domain and a cytosolic domain capable of being phosphorylated.  Much 
like PLB and SERCA, PLM inhibits NKA by reducing ion affinity (Bers & Despa, 2009).  
Taken together, these observations suggest a high likelihood that PLB and PLM interact 
with their partners in a similar way.  Unlike PLB and SERCA, a high resolution crystal 
structure has been determined for PLM and NKA (Shinoda, Ogawa, Cornelius, & 
Toyoshima, 2009).  Rather than showing interaction in the M2/M4/M6 binding groove 
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predicted for PLB, PLM interacts with the more exterior helix M9 of NKA (Fig. 7B).  Due 
to the similarities between the proteins, this suggests the possibility of an alternative 
binding site on SERCA for PLB.  However, this observation has not been supported 
through alternative approaches like crosslinking or mutagenesis, so it could be an 
artifact of crystallization.   While unlikely due to the high degree of similarity, it is also 
possible that PLB and PLM confer inhibition through alternative means and binding 
sites. 
Potential Interacting Proteins 
 While PLB and SERCA are a clear functional unit, one must also consider the 
possibility that additional proteins may interact with PLB and SERCA in a larger protein 
complex.  Therefore, additional proteins may alter SERCA function and the ability of PLB 
to inhibit in a physiological setting.  This has not been a heavily studied area, but there 
are several proteins of interest that have been identified.  As with many proteins that 
can be phosphorylated by PKA, PLB has been found in complex with an A kinase 
anchoring protein (AKAP) and has been shown to affect the phosphorylation status of 
PLB in vivo (Lygren et al., 2007; Manni, Mauban, Ward, & Bond, 2008).  The anti-
apoptotic HS-1 associated protein X-1 (HAX-1) has been shown to interact with SERCA 
and regulate its expression (Vafiadaki et al., 2009).  HAX-1 overexpression has been 
shown to reduce contractility of cardiac myocytes, and this effect was abolished in the 
PLB knockout mouse (Zhao et al., 2009).  HAX-1 was identified as a binding partner of 
PLB using the yeast two-hybrid method (Vafiadaki et al., 2007) and was shown to 
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destabilize PLB pentamer formation (Vafiadaki et al., 2009).  Histidine rich Ca2+ binding 
protein (HRC) is an SR Ca2+ buffering protein that has been shown to have a regulatory 
role in Ca2+ release via triadin and the ryanadine receptor.  Additionally, HRC has been 
shown to interact with SERCA and alter Ca2+ sequestration (D. a Arvanitis et al., 2007; 
Pritchard & Kranias, 2009).  This dual role for HRC suggests a potential crosstalk role 
between Ca2+ uptake and release.   
Disease and Therapy 
Physiological Principles of Disease 
 SERCA activity maintains SR Ca2+ load which is a primary determinant of Ca2+ 
release and contractility (Bers, 2008).  Decreases in SERCA activity would then seemingly 
be associated with reduced contractility, a general characteristic of heart failure.  In 
many observed cases, decreased SERCA activity has indeed been related with heart 
failure (Hasenfuss, 1998; Phillips et al., 1998; Wickenden et al., 1998).  In most but not 
all cases, decreased SR Ca2+ content has been observed with heart failure.  In many 
instances, this decreased SR Ca2+ content has been connected to depressed SERCA 
function.  However, increased activity of the Na, Ca-exchanger has also been implicated 
in reduced SR content when no change in SERCA function was observed (Bers, 2008; 
Hobai & Rourke, 2000; Houser, Piacentino, Mattiello, Weisser, & Gaughan, 2000; 
Pogwizd, 2000).  Depressed SERCA function associated with heart failure can be 
attributed to decreased expression of SERCA2a or enhanced inhibition from SERCA.  
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 There are no mutations in SERCA2a known to cause a predisposition of heart 
failure (Kranias & Bers, 2007).  In the only screen of SERCA2a mutations in heart failure 
patients, only 4 point mutations were found, all of which were conserved mutations 
resulting in no change in the amino acid sequence (Schmidt et al., 2003).  This suggests 
that genetic polymorphisms are not likely to account for differences in SERCA activity in 
heart failure patients.  Darier’s disease is characterized as a haploinsufficiency of the 
SERCA2 gene resulting in a skin disorder (Brini & Carafoli, 2009; Dally, Corvazier, 
Bredoux, Bobe, & Enouf, 2010).  Interestingly however, adult Darier patients are not 
predisposed to heart failure suggesting a robust compensatory mechanism for cardiac 
SERCA expression or sufficient expression from one allele.  It has been speculated that 
the lack of genetic variation within SERCA2a suggests that even minor changes to 
SERCA2a activity cannot be tolerated and are incompatible with life (Kranias & Bers, 
2007).  
 While there are no known SERCA mutations associated with heart failure, there 
have been 3 important mutations identified within PLB associated with dilated 
cardiomyopathy.  A substitution of Arg9 for Cys (R9C) has been shown to impair 
phosphorylation of PLB, thereby enhancing inhibition of SERCA (Brini & Carafoli, 2009; 
Ha et al., 2011; Schmitt et al., 2003).  A premature stop codon at Leu39 (L39stop) has 
been shown prevent proper insertion of PLB into the SR membrane thereby preventing 
its ability to regulate SERCA (Kranias & Bers, 2007).  The deletion of Arg14 (R14del) is 
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thought to enhance the interaction with SERCA, thereby increasing the inhibition of 
SERCA (Haghighi et al., 2006). 
Therapeutic Targets 
Since decreased contractility is a component of heart failure, enhancing SR load 
through increased SERCA activity is a logical therapeutic path.  This concept is supported 
by studies showing that increasing SERCA2a expression levels through gene transfer in a 
failing mouse heart model has be ability to restore contractility (Del Monte, Hajjar, 
Harding, & Inesi, 2001).  In fact this approach is currently in human clinical trials.  
Decreasing the ability of PLB to inhibit SERCA is also a potential target for therapy.  A 
phosphomimetic PLB mutant (S16E) which has a decreased ability to inhibit SERCA has 
been shown to be capable of relieving SERCA inhibition in heart failure (Hoshijima et al., 
2002).  Also ablation of PLB through antisense DNA transfer has been effective in 
restoring contractility in a rat failing heart model (Tsuji et al., 2009).  While PLB ablation 
or replacement with non-inhibitory mutants might provide an effective means of 
restoring contractility, deleterious effects might arise from an inability of SERCA function 
to respond to β-adrenergic stimulation.  Therefore, development of designer PLB 
mutants that have a reduced ability to inhibit SERCA while retaining the ability to 
respond to phosphorylation would be a significant improvement of this approach. 
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CHAPTER III MATERIALS AND METHODS 
Overview of Fluorescence Resonance Energy Transfer 
 Fluorescence Resonance Energy Transfer (FRET) is a highly effective means of 
detecting protein-protein interactions and is the predominant methodology I have 
utilized for this work.  A thorough description of FRET can be found in Principles of 
Fluorescence Spectroscopy 3rd Edition (Lakowicz, 2006), but will a brief description of 
FRET will be provided here. 
 FRET utilizes the biophysical property of appropriately paired fluorescent 
molecules (donor and acceptor) that causes the transfer of light energy when in close 
proximity (<100 Å).  This study uses Cerulean (CFP derivative) and YFP as the donor and 
acceptor fluorophores, respectively.  When Cerulean is excited, the energy can be 
emitted from that fluorophore as a photon of blue light or transferred to YFP (exciting 
YFP) causing the emission of a photon of yellow light.  The percent of the donor 
excitation energy that is transferred to the acceptor is known as a FRET Efficiency (E).  E 
is commonly determined through quantification of the donor and acceptor fluorescence 
intensities.  This work uses the acceptor-photobleaching and E-FRET methods to 
measure FRET and both are discussed in detail below.  When these fluorophores are 
attached to proteins that interact (e.g., SERCA and PLB), the fluorophores can be (but 
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not always) in close enough proximity to undergo energy transfer.   Observed energy 
transfer therefore provides an indicator of interaction of the target molecules.  E is 
highly sensitive to and can measure the distance between the fluorophores (inversely 
related to the distance to the power of 6).  Therefore E is more than just an indicator of 
interaction since it provides some information about the orientation of the interacting 
proteins by producing a distance constraint. 
Acceptor Photobleaching 
Acceptor photobleaching experiments were performed with an inverted 
microscope equipped with a 60X 1.49 NA objective, and a back-thinned CCD camera 
(iXon 887, Andor Technology, Belfast, Northern Ireland).  The detector was cooled to -
100 °C, using a recirculating liquid coolant system (Koolance, Inc., Auburn, WA).  Image 
acquisition and acceptor photobleaching was automated with custom software macros 
in MetaMorph (Molecular Devices Corp, Downingtown, PA) that controlled motorized 
excitation/emission filter wheels (Sutter Instrument Co., Novato, CA) with filters for 
CFP/YFP/mCherry (Semrock, Rochester NY).  The progressive photobleaching protocol 
was as follows: 100 ms acquisition of CFP image, 40 ms acquisition of YFP image, 
followed by 10 s exposure to YFP-selective photobleaching (504/12 nm excitation. FRET 
efficiency was calculated from the fluorescence intensity of the CFP donor before and 
after acceptor-selective photobleaching, according to the relationship:  E = 1 - 
(FPrebleach/FPostbleach).  Representative pre and post bleach images are shown in Fig. 8A  
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Figure 8: Acceptor Photobleaching FRET. (A) CFP and YFP images pre and post YFP 
photobleaching.  After photobleaching, the YFP fluorescence is abolished while CFP 
fluorescence has been enhanced.  (B) Average normalized fluorescence intensity of CFP 
(blue) and YFP (green) during the course of YFP photobleaching.  CFP intensity increases 
with decreasing YFP intensity. 
 
A 
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displaying enhanced CFP fluorescence corresponding to abolished YFP fluorescence.  Fig. 
8B shows the time course of average fluorescent intensity of CFP increasing as average 
fluorescent intensity of YFP decreases. 
E-FRET 
I have also utilized E-FRET or “3-cube” FRET (Hou & Robia, 2010; Zal & 
Gascoigne, 2004) rather than acceptor-photobleaching to improve on the speed to data 
collection.  Measurements are consistent with the well established acceptor 
photobleaching method that our lab has previously used (Hou & Robia, 2010; Hou et al., 
2008; Kelly et al., 2008).  For these measurements, we used a similar microscope setup 
described above for acceptor photobleaching.  For each sample, automated acquisition 
of a field of 48 images was performed using a motorized stage (Prior, Rockland, MA) 
controlled by MetaMorph software.  Focus was maintained by an optical feedback 
system (Perfect Focus System, Nikon).  Images were obtained with a 40X 0.75 N.A. 
objective with 100 ms exposure for each channel: Cer, YFP, and “FRET” (Cer 
excitation/YFP emission).  Fluorescence intensity was automatically quantified with a 
multi-wavelength cell scoring application in MetaMorph.  Cell selection criteria included 
having a diameter of 35-75 pixels and having an average intensity of 100 counts above 
background.  The data were transferred automatically to a spreadsheet for analysis. E-
FRET is a ratiometric FRET estimation calculated from 
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where IAA is the intensity of fluorescence emission detected in the donor channel 
(472/30 nm) with excitation of 427/10 nm; IAA is acceptor channel (542/27 nm) emission 
with excitation of 504/12 nm; IDA is the “FRET” channel, with 542/27 nm emission and 
excitation of 427/10 nm;  a and d are cross-talk coefficients determined from acceptor-
only or donor-only samples, respectively.  We obtained values for d of 0.82 for 
mCerulean, and a value for a of 0.082 for YFP.  G is the ratio of the sensitized emission 
to the corresponding amount of donor recovery, which was 3.2 for this setup.    
Binding Curves and Fitting Analysis 
In addition the distance between the fluorescent probes, the percentage of 
targets engaged in energy transfer determines the FRET efficiency of an individual cell.  
Expression and affinity of the targets will dictate this percentage, causing FRET efficiency 
to vary within a population of cells with heterogeneous protein expression.  When the 
FRET efficiency of individual cells is plotted against PLB protein concentration estimated 
by the YFP-PLB fluorescence intensity, FRET efficiency increases with protein expression 
up to a maximal level and can be well described by a hyperbolic function, y = 
(FRETmax)x/(KD2 + x) An example scatter plot is shown in Fig. 9A along with its 
corresponding hyperbolic fit in black.  300-800 cells are typically used to develop a single 
binding curve.  FRETmax describes the intrinsic FRET between SERCA and PLB where FRET 
is limited only by the distance between the probes, providing structural information (Fig. 
9A, blue).  KD is the protein concentration at half maximal FRET which represents the 
dissociation constant of the regulatory complex providing an affinity index (Fig. 9A, red).   
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Figure 9: Quantitative analysis of protein concentration dependence of FRET.  FRET 
efficiency varies within a population of cells, and can be related to protein concentration 
with a hyperbolic function.  A representative scatter plot of individual cell values is 
shown along with corresponding fitting curve (A, B, black).  (A) The FRET efficiency that 
the fitted curve is approaching is known as FRETmax (blue dashed line), the intrinsic FRET 
value that limited only by the distance between the fluorescent probes.  The protein 
concentration at half maximal FRET efficiency is the KD value (red dashed lines).  (B)  The 
blue line corresponds to a sample with a decreased FRETmax, or increased distance.  The 
red line corresponds to a sample with a reduced affinity. 
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The absolute values of FRET obtained through our methodology include some 
level of uncertainty.  Due to their unstructured linkage with PLB and SERCA, the 
fluorescent proteins likely retain a high degree of flexibility with respect to the target 
proteins.  The fluorescent proteins are also relatively large.  In combination, these two 
factors limit the ability of our method to make precise structural conclusions.  Presently,  
we are unable to determine specific concentrations from these fluorescence 
measurements.  Therefore our concentration parameter is presented in arbitrary units 
(AU) rather than molar units.  Therefore, changes or shifts in these FRETmax and KD 
parameters provide more significant information than do their absolute values.  The red 
and blue curves in Fig. 9B represent simulations of changes in affinity and structure, 
respectively.  The right-shifted curve in red represents where data corresponding to 
reduced affinity should fall.  The down-shifted curve in blue represents a distance 
increase corresponding to a structure change.   
Non-specific FRET, or energy transfer between close but non-interacting targets, 
is a concern with FRET measurement, especially if the targets are constrained to the 
membrane.  While we presently have no true negative control for PLB-SERCA FRET, we 
have estimated non-specific FRET through a competition assay.  Addition of increasing 
amounts of unlabeled protein decreases FRET efficiency in our system to 4% (Hou & 
Robia, 2010).  Therefore, even at the highest expression levels, only 4% of the measured 
FRET efficiency is accounted for by non-specific FRET.  
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Confocal Microscopy 
Confocal Images 
 To verify proper expression of YFP-PLB and Cer-SERCA2a, high resolution 
confocal images were taken of infected myocytes.  To visualize sarcolemma and t-
tubules, cells were also stained with FM 4-64 (Invitrogen) according to manufactures 
instructions.  Briefly, dye at a stock concentration of 1 mM was diluted to a 
concentration of 1 µM in PC-1 medium was used to bathe cells for approximately 10 
min, after which cells were washed in additional PC-1 to remove excess dye.  Images 
were obtained using an inverted Leica TCS SP5 confocal microscope with a 63x water 
immersion objective and an 8000 Hz resonant scanner.  Cer, YFP, and FM 4-64 were 
sequentially excited using an argon laser with wavelengths of 458, 514, and 543 nm, 
respectively.   
Confocal Scanning 
 Confocal scanning microscopy was used obtain simultaneous and high temporal 
resolution of FRET and Ca2+ concentration measurements in paced adult ventricular 
myocytes.  As an index of FRET, the ratio of YFP/Cer fluorescence intensities was 
obtained with 458 excitation and detection of YFP (525-560 nm) and Cer (470-515 nm) 
using the Leica system described above.  Cells were loaded with X-Rhod-1 AM as an 
indicator of Ca2+ concentration which was detected with 543 nm HeNe laser excitation 
and an emission range of 570-650 nm.  Myocytes were perfused with PC-1 medium 
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during data collection.  Experiments were conducted in x-t mode to study individual Ca2+ 
transients and x-y-t mode to study alternating periods of pacing and rest. 
Tissue Culture 
Heterologous Cell Culture and Transient Transfection 
AAV-293 cells were cultured in complete DMEM growth medium (HyClone, 
Waltham, MA) with 10% fetal bovine serum (heat inactivated) (HyClone, Waltham, MA), 
2mM L-glutamine (CellGro, Manassas, VA).  Cells were split every few days once a 
confluency of 90-95% had been reached.  Cells at approximately 70-80% confluency 
were transfected according to manufacturer’s instructions, using MBS Mammalian 
Transfection Kit (Stratagene, La Jolla, CA).  6% modified bovine serum was used instead 
of the 10% suggested by the manufacturer during the three hour incubation of cells with 
the CaPO4-DNA precipitate.  Two days after transfection, cells were trypsinized and 
plated onto poly-D-lysine coated glass bottom dishes and incubated at 37 C for 
approximately 2 hours to permit cell attachment before data acquisition. 
For Tg exposure, cells were washed 2 times with PBS, and then bathed in PBS 
containing the appropriate concentration of Tg, 10 pM – 100 uM.  For Ca2+ experiments, 
cells were permeabilized with 10 µg/ml saponin for 1 min. and then washed in bath 
solution of composition 100 mM KCl, 5 mM NaCl, 2 mM MgCl2, 20 mM imidazole, 5 mM 
EGTA, and 2 mM ATP (pH 7.0), with varying free Ca2+.  Ca2+ concentration was calculated 
with Maxchelator (Schoenmakers, Visser, Flik, & Theuvenet, 1992) and validated with a 
Ca2+-sensitive electrode (Thermo Scientific, Waltham, MA). 
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Myocyte Culture and Adenoviral Infection 
 The Ca2+ phosphate transfection system used to express our fusion proteins in 
AAV-293 is insufficient for expression in adult myocytes.  We therefore developed 
adenoviral vectors of canine Cer-SERCA2a and canine YFP-PLB using the AdEasy system 
(Stratagene, La Jolla, CA).  Cardiac ventricular myocytes were isolated from adult New 
Zealand White rabbits by a collaborating lab as previously described (Domeier, Blatter, 
& Zima, 2009).  All protocols were approved by the Loyola University Institutional 
Animal Care and Use Committee.  Myocytes were transferred to culture tubes and 
washed with PC-1 medium (Lonza, Basel, Switzerland) containing penicillin and 
streptomycin (Invitrogen). 
Myocytes were cultured in dishes containing laminin coated glass coverslips and 
adenoviruses were added at multiplicity of infection of 100.  Sufficient expression of our 
constructs required approximately 48 hours of culture, however viability of the 
myocytes declines rapidly.  To improve viability, myocytes were paced in culture using a 
C-Pace EP pacer (IonOptix, Milton, MA) set to 10 volts with a frequency of 10 Hz and 5 
ms pulse duration. 
Calcium Indicator 
 Experiments required both AAV-293 and adult myocytes to be loaded with a red-
shifted fluorescent Ca2+ indicator, X-Rhod-1 AM (Invitrogen).  The dye was resuspended 
in Pluronic® F-127 *20% solution in DMSO (Invitrogen) to a concentration of 1 mM, and 
sonicated briefly to aid in solubilization.  This stock solution was diluted to 1 µM in 
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either PBS or PC-1, which was used to bathe the cells for 2 min.  Cells were then washed 
gently 3x in either PBS or PC-1 and equilibrated for 20 min prior to imaging. 
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CHAPTER IV LIVE CELL CALCIUM UPTAKE ASSAY 
Rationale for Development of Assay 
 Much of the work done for this dissertation and other work in our lab utilizes 
fluorescent protein fusions.  These fusion proteins enable the detection of protein-
protein interactions with FRET in live cells, in real-time.  While this methodology 
provides significant advantages, it is not without drawbacks.  How the attachment of 
relatively large fluorescent proteins will affect our target proteins is a valid concern.  
Therefore, assessing the functionality of our fusion proteins is a necessary step in 
validating our overall approach. 
 Traditional SERCA activity assays such as ATP consumption and Ca2+ uptake are 
needed to quantify the activity of SERCA and the ability of PLB to inhibit this activity.  
These assays are necessary to directly compare the activities of wild type SERCA and PLB 
to our fusion proteins.  However, these assays can be difficult and time consuming.  
Having an alternative method to rapid screen for function is therefore highly beneficial 
for our lab.  To complement more direct quantification of our fusion protein activity that 
our lab has undertaken, we developed an indirect live cell Ca2+ uptake assay, the 
particulars of which are discussed below. 
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Protocol 
 AAV-293 cells are transfected with various constructs as discussed previously.  24 
hours post-transfection, cells are plated on poly-D-lysine coated glass slides, and 
allowed to attach for 2 hours also discussed previously.  Ca2+ indicator loading is 
described in the Materials and Methods section.  Briefly, cells are washed 2 times with 
PBS containing 2 mM Ca2+ and loaded with a red-shifted Ca2+ indicator, X-Rhod-1, AM.  
Cells are washed an additional 3 times to remove excess dye, and cells are bathed in PBS 
containing 2 mM Ca2+ for 20 min. 
First, a 100 ms CFP or YFP is taken to assess transfection status of cells in a given 
field of view. Then a mCherry or red channel image is then taken every 5 secs for 
approximately 8 min (100 images).  At the 1 min time point, a sufficient baseline X-Rhod 
signal has been obtained, at which 100 µM ATP is added to the cells.  4 min later, 10 mM 
thapsigargin is added, and data collection continues for approximately 3 more minutes.  
The mean X-Rhod and std. error of 30-60 cells is plotted against time. 
With typical transfection efficiency around 50-60%, there generally is a 
heterogeneous population of transfected and untransfected cells in any field of view.  
This is depicted in Fig. 10A showing CFP, YFP, and red channel images along with the 
corresponding overlay.  This field contains both transfected (T) and untransfected (UT) 
cells.  This allows simultaneous data collection from expressing and non-expressing cells, 
thereby providing an internal control within the experiment. 
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Principle of Assay and Results 
 Activation of cell surface purinergic receptors through ATP stimulation induces 
an IP3 mediated Ca
2+ release in many cell types, including AAV-293 (Ralevic & Burnstock, 
1998).  Endogenous SERCA Ca2+ uptake is initially overwhelmed by this release event, 
causing Ca2+ to accumulate in the cytosol.  Desensitization of purinergic receptors and 
IP3 degradation halts Ca
2+ release, preventing further accumulation, and allowing the 
endogenous SERCA to lower cytosolic Ca2+ to basal concentrations.  If cells are loaded 
with a fluorescent Ca2+ dye, a spike in fluorescence intensity following ATP stimulation 
will be observed (Fig. 10B, black).  In cells overexpressing our Cer-SERCA, we observed 
that this spike was nearly abolished (Fig. 10B, red).  We believe that enhanced SERCA 
activity due to overexpression of our fusion protein is able to keep pace with the Ca2+ 
release, thereby preventing Ca2+ accumulation.   
Because we do not directly measure Ca2+ uptake activity, abolishing Ca2+ 
accumulation alone is not sufficient to demonstrate SERCA function.  Overexpression of 
our fusion proteins (Cer-SERCA, YFP-PLB) could deleteriously affect the cell, perhaps 
causing a depletion of the ER Ca2+ stores that would prevent a Ca2+ release and 
accumulation.  There is a constant leak of Ca2+ from the ER, but basal SERCA Ca2+ uptake 
maintains low cytosolic Ca2+ concentrations.  Blocking SERCA activity will then cause 
accumulation of cytosolic Ca2+.  By applying the SERCA inhibitor thapsigargin (Tg) 
following ATP stimulation, we are also able to assess ER Ca2+ content of these cells.   
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Figure 10: Ca2+ uptake in live cells.  (A) Wide-field fluorescence images of AAV-293 cells 
transfected with Cer-SERCA and YFP-PLB, loaded with Ca2+ indicator X-rhod-1. This field 
contains examples of transfected (T) and untransfected (UT) cells. (B) Ca2+ transients 
were observed after the addition of extracellular ATP in untransfected cells (black), but 
not in cells expressing Cer-SERCA (red), suggesting Ca2+ uptake activity of Cer-SERCA. 
Ca2+ transients were partially restored in cells expressing both Cer-SERCA and YFP-PLB 
(blue). When compared with untransfected controls, Tg-releasable ER Ca2+ content was 
increased by Cer-SERCA. Cells expressing YFP-PLB (green) had reduced Ca2+ transients 
and reduced Ca2+ load, suggesting that exogenous PLB inhibited endogenous SERCA. 
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In both untransfected (Fig. 10B, black) and cells expressing exogenous SERCA 
(Fig. 10B, red), we observed this Tg-mediated Ca2+ accumulation, demonstrating that 
expression of our fusion protein does not deplete Ca2+ stores.  In fact, cells 
overexpressing Cer-SERCA show a greater Tg-mediated Ca2+ accumulation compared to 
untransfected cells, suggesting a greater ER Ca2+ content.  This provides further 
evidence of enhanced Ca2+ uptake upon overexpression of our SERCA fusion protein. 
Co-expression of Cer-SERCA with YFP-PLB partially restores the ATP-mediated 
Ca2+ accumulation to control levels suggesting that YFP-PLB can functionally inhibit Cer-
SERCA (Fig. 10B, blue).  Also, this further demonstrates the activity of Cer-SERCA, since 
its known inhibitor can diminish its observed effect.  Expression of YFP-PLB alone (Fig. 
10B, green) showed smaller ATP and Tg-mediated Ca2+ accumulation compared to 
untransfected cells, indicating YFP-PLB can regulate endogenous SERCA.   
Summary 
 This assay provides a rapid and clear qualitative assessment of our fusion protein 
activity.  We observed that Cer-SERCA1a is active, which can be functionally regulated 
by YFP-PLB.  We also observed that Cer-SERCA2a is also active and can be functionally 
regulated by YFP-PLB (not shown).  While not used in this work, we have also observed 
that a SERCA tagged with two fluorescent proteins (one of which is inserted in the 
middle of SERCA) is also active and can be regulated by YFP-PLB (not shown).  This 
demonstrates that robustness of our system, wherein a complex containing 3 
fluorescent proteins can remain functional. 
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CHAPTER V STEADY-STATE DETECTION OF PLB-SERCA BINDING 
Rationale 
 As discussed in the Literature Review, multiple models of PLB regulation have 
been proposed, but no clear consensus has been achieved despite extensive research on 
this interaction.  Chemical crosslinking, immunoprecipitation, and FRET studies have 
been used to investigate the steady-state PLB-SERCA interaction under various 
conditions that favor particular conformations of SERCA.  In addition to their strengths, 
previous methods have significant limitations.  This necessitates additional points of 
view from new and alternative approaches.  We have used FRET in intact cells to 
quantitatively study the PLB-SERCA interaction, a method that has its own strengths and 
weaknesses.  By using this complementary method, we have sought to tease out some 
nuances of the PLB-SERCA interaction and integrate the present data in the field into a 
cohesive model.  
Mean FRET 
Thapsigargin (Tg) is a cell permeable SERCA inhibitor commonly used to block the 
Ca2+ uptake of intact cells (Michelangeli & East, 2011).  Tg has also been shown to 
completely block chemical crosslinking between PLB and SERCA in isolate vesicles (Chen 
et al., 2006, 2005; Jones et al., 2002).  We therefore initially hypothesized that Tg would 
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completely displace PLB from SERCA, and therefore completely abolish PLB-SERCA FRET 
in intact AAV-293 cells.   To test this hypothesis we exposed the cells transiently 
expressing YFP-PLB and CFP-SERCA1a to either 1 µM Tg or vehicle control in PBS for 10 
min.  Using the acceptor photo-bleaching method, we then measured the average FRET 
efficiency.   We observed that the Tg decreased average FRET efficiency from 13.4 
± 1.7% to 5.2 ± 1.1% (Fig. 11A).  FRET between PLB and SERCA was decreased, but not 
abolished.   
In a parallel experiment, we examined the effect of Ca2+ on the average PLB-
SERCA FRET.  As with Tg, we hypothesized that Ca2+ would completely displace PLB from 
SERCA based upon chemical crosslinking studies, and therefore completely block PLB-
SERCA FRET in AAV-293 cells.  Cells expressing YFP-PLB and CFP-SERCA1a were bathed in 
10 µM ionomycin, a Ca2+ ionophore, for 10 min in PBS with or without 1.8 mM Ca2+.  
FRET was then measured in these cells as before.  FRET was not significantly decreased 
by the presence of high Ca2+ (21.4 ± 2.2% at low Ca2+ and 18.8 ± 2.3% at high Ca2+) (Fig. 
11C). 
Antibodies targeting PLB have been previously shown to block the ability of PLB 
to inhibit SERCA (Cantilina et al., 1993) as well as block PLB-SERCA crosslinking (Chen et 
al., 2007).  In an additional experiment, we examined the effect of rabbit anti-PLB 
(2D12) on PLB-SERCA FRET in AAV-293 cells.  Cells expressing YFP-PLB and CFP-SERCA1a 
were permeabilized using 20 mg/ml saponin and then bathed in PBS with or without  
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Figure 11: Mean PLB-SERCA FRET.  The mean PLB-SERCA FRET is decreased by (A) Tg and 
(B) PLB antibody (2D12), but not by (C) elevated calcium concentration. 
A 
C 
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2D12 antibody.  FRET was then measured in these cells using the acceptor-
photobleaching method.  Average FRET was reduced by PLB antibody to 3.9 ± 1.2% from 
a control of 9.7 ± 1.1% (Fig. 11B).  FRET again was not completely abolished as was 
initially hypothesized. 
These average FRET results were inconsistent with the published crosslinking 
studies which predicted we would observe a complete blockage of FRET with Ca2+, Tg, or 
PLB antibody (Chen et al., 2007, 2006, 2005).  We observed no significant reduction in 
FRET with high Ca2+ concentrations, and only partially reduced FRET in the presence of 
Tg and PLB antibody.  The lack of the predicted effects could be due to several factors.  
Our experimental conditions could have insufficiently saturated our system (incomplete 
binding of Ca2+ and Tg to SERCA or 2D12 to PLB) thereby preventing the full dissociation 
of PLB from SERCA.  However, our initial hypothesis that PLB would completely 
dissociated PLB from SERCA may have also been incorrect. 
Protein Dependence of FRET 
  Using average FRET efficiency from a population of cells as an indicator of 
protein-protein interaction is simple and straight forward, but is also very limiting.  We 
can detect binding and changes in binding, but cannot fully describe these changes.  A 
decrease in average FRET efficiency could be caused by unbinding or dissociation of a 
portion of the proteins undergoing FRET indicating a decrease in affinity.  Also, there 
could be an increase in the distance between our probes attached to our target proteins 
indicating a structure change.  We decided further experiments should be analyzed 
61 
 
using a standard lab protocol showing the dependence of FRET efficiency of a cell on its 
protein expression level.  This approach has been shown to distinguish between changes 
in affinity (KD2) and structure (FRETmax) of the PLB-SERCA regulatory complex (Ha et al., 
2011; Hou & Robia, 2010; Hou et al., 2008; Kelly et al., 2008) as well as the Na, K-
ATPase-phospholemman interaction (Song, Pallikkuth, Bossuyt, Bers, & Robia, 2011).   
We are able to observe a clear trend when we plot FRET efficiency of many cells 
against their protein concentration, estimated by YFP fluorescence intensity (Fig. 9).  In 
control cells, FRET increases with protein concentration up to a maximal level and is 
described by a hyberbolic function of the form y = (FRETmax)x/(KD2 + x).  FRETmax and KD2 
values are consistent with previously published work from this lab.  Addition of 10 uM 
Tg, as described above, causes a rightward shift of the fitted curve (Fig. 12A).  KD2 is 
increased from 7.0 to 11.9 AU.   We observed no change in the FRETmax parameter.  
These two observations suggest that the decrease in average FRET was due to a 
decrease in the amount of PLB interacting with SERCA and not an increase in the 
distance between the two proteins.  While there is reduced binding, there is not a 
complete abolishment in binding that we initially hypothesized based on the crosslinking 
experiments.   
 Using this same approach, we further analyzed the Ca2+ effect on PLB-SERCA 
binding.  Unlike the mean FRET experiment, we utilized PBS containing 1 mM EGTA, 
along with 10 µM ionomycin, to further lower Ca2+ concentration.  This condition 
produced a typical curve approaching a FRETmax of 30.6%.  Addition of 2 mM Ca
2+ caused  
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Figure 12: Protein dependence on FRET, acceptor photobleaching.  Both (A) Tg and (B) 
elevated calcium cause a rightward shift in the dependence curves, describing a reduced 
PLB-SERCA binding affinity. 
A 
B 
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a slight rightward shift of the data (Fig. 12B).  The control and high Ca2+ datasets 
overlap, but are clearly resolvable with an increase of KD2 from 4.5 to 6.0 AU.  As with 
Tg, the Ca2+ effect on PLB-SERCA binding can be described as a decreased affinity, 
partially reducing binding, but not completely abolishing it.  
This is unlike the mean FRET result shown previously where no significant Ca2+ 
effect was observed.  Several factors could explain this discrepancy.  Use of EGTA could 
have partially lowered the control KD2 value thereby producing a change that was not 
present in the mean FRET experiment.  Also, with the high degree of overlap in the 
datasets and a relatively small change in KD2, about a 30% increase, the change may 
have been too subtle to observe with the mean FRET approach.  This extra dimension 
provides an advantage of this binding curve FRET analysis of discerning very subtle 
changes.   
E-FRET rationale 
Although we observed clear results from the acceptor photobleaching approach, 
we opted for the E-FRET method to improve the rate of data collection.  A two condition 
plot such as Fig. 12 would require a full day of data collection, whereas a comparable E-
FRET plot would take only a few minutes.  Therefore it is much easier to compare data 
from many different conditions.   With acceptor photobleaching, the time of Tg/ Ca2+ 
exposure would vary between 30-120 minutes.  Due to the shorter time frame of data 
collection, Tg or Ca2+ exposure could be more directly controlled, thereby reducing 
variability within samples.  Additionally, a typical E-FRET plot would have a much larger 
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sample size as an added benefit.  Fewer coverslips and transfected cells are needed also 
improving cost effectiveness of the assay as well.   
E-FRET requires calculations with more variables and assumptions, thereby 
producing more uncertainty in the absolute FRET efficiencies measured.  However, we 
observed consistent results with acceptor photobleaching and E-FRET for both the Tg 
and Ca2+ effects.  The FRETmax parameters were similar between the two approaches.  
Because of the different microscope setups used, the KD2 values of the fitted curves, 
measured in AU, are not the same between the approaches, but the magnitude of the 
KD2 shifts are similar.  Because my conclusions are based more on the relative changes 
of these curves rather than the specific values, E-FRET was the most effective option for 
further experimentation. 
Calcium Dose Effect 
 Rather than using ionomycin, we opted to saponin-permeabilize our cells to 
introduce internal solutions with EGTA buffered Ca2+ to more directly control Ca2+ 
concentration.   Cells expressing Cer-SERCA1a and YFP-PLB were permeabilized with 10 
µg/ml saponin for 1 min. and then washed in bath solution of composition 100 mM KCl, 
5 mM NaCl, 2 mM MgCl2, 20 mM imidazole, 5 mM EGTA, and 2 mM ATP (pH 7.0), with 
varying free Ca2+.  Free Ca2+ concentration was calculated with Maxchelator.   
 After 2-3 min in bath solution, the automatic E-FRET acquisition protocol was 
performed for each Ca2+ concentration.  The fluorescence intensities of cells were 
quantified using the Metamorph multiwavelength application, from which FRET 
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efficiencies were generated as previously described.  Five independent experiments 
were performed.   
Initially, all datasets were fit by a hyperbolic function of the form y = 
(FRETmax)x/(KD2 + x), with all parameters independently fit.  Because mean FRETmax was 
not significantly different for low and high concentrations of Ca2+, we concluded that 
FRETmax did not change in response to changes in Ca
2+.  Therefore, this parameter was 
shared in a subsequent global analysis, yielding a single FRETmax fit with independent KD2 
values for each condition.   
A typical plot of is shown in Fig. 13A for low (100 pM) and high (1 mM) Ca2+ 
concentrations with their corresponding fitted curves.  The data points are pooled for 
visualization, showing average data with error bars corresponding to standard error.  A 
similar Ca2+ effect was observed with cell permeabilization compared to ionomycin 
treatment used previously producing an approximately 40% increase in KD2 value.  The 
KD2 values generated from all data sets were then plotted against Ca
2+ concentration.  
Fig. 13B shows the dependence of KD2 on increasing Ca
2+ concentration.  A modified Hill 
function shows a 41% increase in KD2 with Ca
2+, with an EC50 of 410 nM and a Hill 
coefficient of 1.1.  
Calcium Electrode 
 Since the Maxchelator predicted free Ca2+ concentrations are just theoretical 
estimations, they require further validation.  Fig. 14A depicts the dose response of Ca2+ 
using solutions containing 1 mM EGTA, corresponding to the predicted Maxchelator  
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Figure 13: Calcium effect on PLB-SERCA FRET, E-FRET.  (A) As with acceptor 
photobleaching, elevated calcium (red) causes a right-shifted curve compared to control 
(black) corresponding to a decreased PLB-SERCA affinity with no change in the FRETmax 
parameter (B) The calculated KD2 values from the example fitted curves in A are shown 
plotted against calcium concentration.  KD2 appears to transition between two affinity 
states upon elevation of calcium. 
 
A 
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Figure 14: Calibration of calcium buffered solutions.  (A) The initial calcium response 
curve with an EGTA of 1 mM with the calcium concentration values measured estimated 
by MaxChelator.  (B) The calcium calibration curve of our prepared solutions with 1 mM 
EGTA (red) compared to standard solutions (black).  While in agreement at high calcium 
concentrations, our solutions deviated from the known standard solutions at lower 
concentrations.  (C) The dose curve in A with calcium concentration adjusted using the 
voltage curve in B showing that the low calcium solutions were all clustered around the 
same concentration.  The red curve shows the original fitted curve in A, and the blue 
and green curves show other potential curves that could also fit the data set.  An 
estimate of the high affinity (low KD) state was therefore unable to verified using only 1 
mM EGTA.  (D) The calcium calibration curve of our prepared solutions with 5 mM EGTA 
(red) compared to standard solutions (black) showing agreement of the full range of 
calcium concentrations. 
A 
C 
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values.  Using a Ca2+ sensitive electrode (Thermo Scientific), we compared the free Ca2+ 
concentration of our solutions, to a set of standard Ca2+ solutions (World Precision 
Instruments).  As shown in Fig. 14B, we observed good agreement with the standards at 
concentrations above 100 nM, but deviation from the standards at lower 
concentrations.   
Our initial Ca2+ dependence plot is shown in Fig. 14C after correction with the 
standard concentration curve.  With the low Ca2+ data points clustered around 100nM, 
we could not conclude that we were accurately quantifying the lowest possible KD2 
value.  The blue and green curves represent simulations that could also fit the data, 
showing large differences in the potential low KD value.  By increasing EGTA 
concentration from 1 mM to 5 mM, our prepared solution were in good agreement with 
the standards over the full range of concentrations (Fig. 14D).  The experiments were 
then independently repeated 5 times with the newly determined solutions.  With the 
increased EGTA concentration, a slightly larger increase in the KD2 change was observed, 
but the overall trend remained the same.  While it did not alter our final conclusions, we 
further validated our methodology. 
Thapsigargin Dose Effect 
 Using the same high-throughput E-FRET described for Ca2+, we quantified the Tg 
effect over a range of Ca2+ concentrations, 10 pM to 100 uM, in AAV-293 cells 
expressing YFP-PLB and Cer-SERCA1a (Fig. 15A).  This dose response was repeated with 
4 independent experiments.  As with acceptor photobleaching, we observed a rightward 
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shift to the concentration dependence of PLB-SERCA FRET signifying an increased KD2 
value, or a decreased affinity.   
Initially, all datasets were fit by a hyperbolic function of the form y = 
(FRETmax)x/(KD2 + x), with all parameters independently fit.  Because mean FRETmax was 
not significantly different for low and high concentrations of Tg, we concluded that 
FRETmax did not change in response to changes in Tg.  Therefore, this parameter was 
shared in a subsequent global analysis, yielding a single FRETmax fit with independent KD2 
values for each condition.   
A typical plot of is shown in Fig. 15A for low (10 pM) and high (100 uM) Tg 
concentrations with their corresponding fitted curves.  Mean KD2 (+SE) values generated 
from all data sets were then plotted against Tg concentration (Fig. 15B).  A modified Hill 
function shows a 78% increase in KD2 with Ca2+, with an EC50 of 350 nM and a Hill 
coefficient of 0.7. 
PLB Antibody Effect 
 In a continuation of the mean FRET experiments, we also quantified the protein 
concentration dependence of FRET in the presence of the PLB antibody 2D12.  AAV-293 
cells expressing Cer-SERCA1a and YFP-PLB were permeabilized with 50 µg/ml saponin 
for 1 min. and then washed in bath solution of composition 100 mM KCl, 5 mM NaCl, 2 
mM MgCl2, 20 mM imidazole, 1 mM EGTA, and 2 mM ATP (pH 7.0), containing 10 µg/ml 
2D12 PLB antibody.  The E-FRET protocol was performed at 5, 30, and 120 minutes on 
the same cells in the presence or absence of antibody, to determine the protein  
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Figure 15: Tg effect on PLB-SERCA FRET, E-FRET.  (A) As with acceptor photobleaching, 
elevated Tg (red) causes a right-shifted curve compared to control (black) corresponding 
to a decreased PLB-SERCA affinity with no change in the FRETmax parameter (B) The 
calculated KD2 values from the example fitted curves in A are shown plotted against TG 
concentration.  KD2 appears to transition between two affinity states upon elevation of 
Tg. 
 
A 
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dependence on FRET.  At the 5 min. time point, no change in FRET was observed from 
exposure to PLB antibody (not shown).  PLB antibody greatly reduced PLB-SERCA FRET at 
30 min (Fig. 16A), and to a greater extent at 120 min (Fig. 16B).  At both time points, 
there appears to be a reduction in the FRETmax parameter without a change in the KD2 
value.  More attempts are needed to determine significance.   
Additionally, increased incubation time, higher antibody concentrations, and 
more robust permeabilization could conceivably produce a larger effect by the PLB 
antibody.  Further tests are also needed to verify that a maximal effect has been 
achieved before more explicit conclusions can be made.  Attempts to generate a longer 
time point (overnight) failed to produce usable data because of sample degradation.  
Any future experiments should also include nonspecific IgG as control rather than no 
antibody.  However, this may suggest that the antibody may not fully dissociate PLB 
from SERCA.  The reduction in FRETmax would suggest an altered structure of the PLB-
SERCA complex. 
PLB-PLB FRET 
 To assess PLB pentamer formation, we also quantified FRET in cells co-expressing 
Cer-PLB and YFP-PLB using the E-FRET method.  Cells were either exposed to 10 mM Tg 
or had Ca2+ controlled to low (1 nM) and high (1 mM) concentrations with EGTA 
buffered solutions as in PLB-SERCA FRET experiments described earlier.  Neither Tg 
exposure or changes in Ca2+ concentrations affected the FRETmax or KD1 parameters, 
(Bidwell et al., 2011) and FRETmax value of 54.2 ± 0.7 is consistent with previously  
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Figure 16: PLB antibody (2D12) effect on PLB-SERCA FRET. The protein dependence of 
FRET in the absence (black) and presence (red) of PLB antibody after (A) 30 min and (B) 
120 min incubation times. 
A 
B 
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measured values (Hou et al., 2008; Kelly et al., 2008).  This demonstrates that neither 
our exposure of Tg or changes in Ca2+ concentrations alter pentamer structure or 
affinity, which was expected since neither Tg or Ca2+ have been predicted to directly 
interact with the PLB pentamer. 
 Since PLB exists in a coupled equilibrium (Fig. 4), this demonstrates that our 
observed decreases in PLB-SERCA affinity by Ca2+ (Fig. 13) and Tg (Fig. 15) are not caused 
my increases pentamer affinity.  With no change in PLB-PLB FRET observed, this 
demonstrates that our methods of Tg exposure and control of Ca2+ concentration do not 
have an effect on fluorophore stability or membrane dynamics that could globally 
decrease FRET efficiency or membrane protein affinity.  Therefore, the absence of PLB-
PLB FRET changes provides a good control experiment validating our methodology and 
demonstrating that our PLB-SERCA effects are specific. 
Summary 
 We observed a decrease in PLB-SERCA FRET in response to increases in Ca2+ and 
Tg concentration.  This decrease can be attributed to a reduced affinity, as observed by 
an increased KD2 value.  With no change in the FRETmax parameter, no change in the 
distance between the fluorescent probes was observed.  However, some structural 
rearrangement decreasing the strength of the intermolecular contacts must account for 
the decrease in affinity.  This structure change is likely just not accompanied by a change 
in the position of the fluorescent probes.   
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We observed KD2 increases in response to increases in Ca
2+ and Tg 
concentrations up to a maximal level corresponding to a transition in the affinity of the 
PLB-SERCA regulatory complex.  We therefore believe that the Ca2+ dose response (Fig. 
13B) shows PLB transitioning from binding the E2 (Ca2+ unbound) and the E1 (Ca2+ 
bound) conformations of SERCA.  So even at saturating Ca2+ concentrations known to 
fully relieve PLB inhibition of SERCA, significant PLB-SERCA binding is still observed.  This 
suggests that unbinding of PLB is not required for relief of PLB-SERCA inhibition. 
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CHAPTER VI SERCA INTERACTION WITH TRUNCATED PHOSPHOLAMBAN 
Rationale 
 To account for our data in the previous chapter as well as other data in the field, 
we propose the Domain Displacement Model where high Ca2+ concentrations displace 
the transmembrane domain of PLB to a second binding site on SERCA with no change in 
the position of the cytosolic domain.  To directly test this model, we need to assess 
changes in position of the transmembrane which could not be accomplished in my 
earlier studies.  Since YFP is N-terminally linked to PLB in previous studies, we are only 
able to confirm that the position of the cytosolic domain does not change in response to 
Ca2+.  If the transmembrane domain is displaced independently of the cytosolic domain, 
the position of YFP would not change in response changes in Ca2+ concentration 
To take this factor into account, we have sought to quantify FRET between 
SERCA and a truncated PLB which lacks the cytosolic domain.  An N-terminally linked YFP 
would then be contiguous with transmembrane domain.  Therefore, if the 
transmembrane domain is displaced to an alternative binding site, we expect to see a 
change in our FRETmax parameter unlike with full-length PLB. 
A concern with truncating PLB is that it may not then properly interact with 
SERCA; therefore assessing its interaction would not be sufficient to test our hypothesis.  
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Previous studies have shown that truncated PLB corresponding to residues 25-52 
(Hughes et al., 1996) and 28-52 (Y Kimura et al., 1996) are capable of fully inhibiting 
SERCA activity.  These results provide some feasibility of our approach 
Vector Construction 
 The sequence corresponding to residues 28-52 of canine PLB was amplified with 
PCR, the product of which included BglII and HindIII restriction sites.  A double digestion 
and ligation were performed inserting amplified region of PLB into the eYFP-C1 vector 
(Clontech) at the multiple cloning site, generating YFP-tmPLB.  A complementary vector, 
Cer-tmPLB, was produced by performing a double digest and ligation with YFP-tmPLB 
and pmCerulean-C1 (Clontech) using the BglII and HindIII restriction sites.  Both vectors 
have a 7 residue spacer between the N-terminus of residues 28-52 of PLB and the 
fluorescent protein, coming from the remaining sequence in the multiple cloning site. 
Simulation of tmPLB FRET 
 Using Pymol, we estimated the anticipated distance changes produced by YFP-
tmPLB, compared to full-length PLB, using the PDB structures represented in Fig. 17A.  
Since the positions of the fluorescent probes are unknown, some uncertainty in the 
distance measurements, the estimations were made by applying distance changes to 
the observed distance calculated from the FRETmax value generated by the steady-state 
experiments.  I first measured the distance between the N-terminus and residue 28 of  
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Figure 17: FRET between YFP-tmPLB and Cer-SERCA.  Simulated binding curves based on 
PDB structure measurements (A) and experimentally observed binding curves (B) with  
wtPLB shown shaded and dashed and tmPLB shown in solid.  (A) At low calcium 
concentration (black), our model predicts that decrease in FRETmax with tmPLB with a 
further decrease at high calcium (red).  (B)  At low calcium, we observe the expected 
decrease in FRETmax (black), but do not observe the expected additional decrease at 
high calcium concentration (red). 
A 
B 
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PLB to account for the truncation.  I then measured the distance between the predicted 
binding pocket of helices M2/M4/M6 and the exterior position of helix M9. 
Calcium Effect 
 FRET was quantified by the E-FRET method while Ca2+ concentration was 
controlled as previously described in cells expressing Cer-SERCA1a and either YFP-PLB 
(full-length) or YFP-tmPLB.  As seen previously, saturating Ca2+ (1 mM) caused a 
rightward shift in the curve describing protein dependence of FRET compared to low 
Ca2+ (< 1 nM) for YFP-PLB expressing cells, shown in Fig. 17B with the shaded, dashed 
lines.  At low Ca2+ concentration in cells expressing YFP-tmPLB, the anticipated decrease 
in FRETmax to 20.1% was observed (Fig 17B, black).  However, saturating Ca
2+ 
concentrations had no effect on the protein dependence of FRET in these cells (Fig. 17B, 
red).  Neither the anticipated increase in KD2 or further decrease FRETmax was observed, 
suggesting that no change in the binding of YFP-tmPLB and Cer-SERCA1a occurred. 
YFP-tmPLB Activity 
 To fully characterize the YFP-tmPLB that was used in the above experiment, we 
assessed its ability to inhibit SERCA activity using the Live Cell Calcium Uptake Assay 
described previously.  Expression of Cer-SERCA1a alone greatly reduces the ATP 
mediated Ca2+ accumulation observed in untransfected cells.  However, co-expression of 
YFP-tmPLB does not attenuate the SERCA effect (Fig. 18B) as previously observed with 
YFP-PLB (full-length) (Fig. 10).  Interesting this suggests that YFP-tmPLB does not 
functionally regulate Cer-SERCA1a despite being able to interact. 
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Figure 18: Characterization of tmPLB.  (A) tmPLB pentamer FRET has an increased 
FRETmax compared to wtPLB consistent with truncation o f the cytosolic domain.  The 
KD1 parameter is the same for both tmPLB and wtPLB.  (B) tmPLB does not restore the 
ATP dependent calcium accumulation in our in cell activity assay when co-expressed 
with Cer-SERCA. 
A 
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Pentamer FRET 
 To further characterize YFP-tmPLB, we also assessed its ability to bind to itself by 
measuring FRET between YFP-tmPLB and Cer-tmPLB using the E-FRET method described 
previously.  In cells expressing full length PLB tagged with YFP and Cer, we observed a 
FRETmax of 53.1% (Fig. 18A, black), consistent with values obtained previously (Bidwell et 
al., 2011).  In cells expressing YFP-tmPLB and Cer-tmPLB, we observed an increased 
FRETmax to 60.9% (Fig. 18A, red) consistent a decreased distanced produced with 
removal of the cytosolic domain placing the fluorescent closer to together.  The same 
KD1 value was observed for both full length and truncated PLB, demonstrating that 
truncation of PLB in YFP-tmPLB does not alter pentamer affinity. 
Summary 
A change in the FRETmax parameter was not observed when saturating Ca
2+ was 
added to cells expressing YFP-tmPLB and Cer-SERCA1a.  Therefore, the movement of the 
transmembrane domain to an alternative binding site was not observed as predicted.  
YFP-tmPLB-Cer-SERCA FRET is completely unresponsive to changes in Ca2+ concentration 
with neither the FRETmax nor KD2 parameter changing upon addition of saturated Ca
2+.  
Also, YFP-tmPLB does not appear to functionally regulate SERCA activity.  Taken 
together, these observations suggest that YFP-tmPLB does not associate with SERCA as 
does full-length PLB.   
However, YFP-tmPLB does interact with SERCA since it expresses correctly in the 
ER and undergoes FRET with Cer-SERCA1a.  The FRETmax parameter is decreased to 
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20.1% compared to 28.2% in full length expressing cells.  This decrease is consistent with 
a change in the position of YFP attached to a truncated PLB, as predicted by distance 
measurements of the PDB structure.  Also, the observed KD1 parameter (pentamer 
affinity) is the same for both full-length and truncated PLB.  These observations suggest 
that YFP-tmPLB retains some binding characteristics of full-length PLB despite inability 
to regulate SERCA and unresponsiveness to changes of Ca2+ concentration. 
Presently, we hypothesize that steric hindrance of the fluorescent protein in YFP-
tmPLB prohibits functional interaction with SERCA, thereby preventing its ability to 
regulate SERCA and to respond to Ca2+.  Changes to the YFP-tmPLB construct may then 
allow proper interaction.  The planned changes and further characterization of the 
current YFP-tmPLB construct are reviewed in detail in the Discussion section. 
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CHAPTER VII REAL-TIME PLB-SERCA FRET 
Rationale 
 To this point, all investigation of the PLB-SERCA interaction has utilized steady-
state biochemical approaches.  Because of the limitations of these studies, little is 
understood about the kinetics and dynamics of this interaction.  A fundamental 
question that remains is how this interaction changes over-time in response to changes 
in Ca2+ concentration.  This question is all the more important considering Ca2+ 
concentrations change rapidly on a millisecond timescale in cardiac and slow twitch 
skeletal muscle, the only PLB expressing tissues.  In the case of cardiac muscle, these 
changes are occurring continuously, on a beat to beat basis of the heart.   
 The range of Ca2+ concentration over which PLB alters the interaction with and 
activity of SERCA corresponds to concentrations of a Ca2+ transient of cardiac myocyte 
(100 nM – 1 µM).  In other words, PLB interaction and inhibition of SERCA could 
theoretically vary over the course of a single Ca2+ transient.  That is if changes in binding 
and inhibition occur on a fast enough timescale, which is undetermined at the present 
time due to limitations of past approaches. 
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 Our FRET system describes a clear change in PLB-SERCA FRET in response to 
elevated Ca2+.  This change occurs in the same range of Ca2+ response to assays 
predicting complete dissociation, suggesting that the approaches are compatible and 
detect the same change in binding.  The variations in the approaches produce a 
different observable endpoint, favoring different mechanistic models.  A significant 
benefit of our system over all other methods is that we can detect changes in PLB-
SERCA binding in real time within intact cells.  Therefore, our methodology has the 
potential to investigate the time domain of this interaction, no matter the explicit model 
of PLB-SERCA interaction. 
 Evidence of the timescale of PLB-SERCA binding comes from earlier work from 
our lab (Robia et al., 2007).  Using a FRET recovery after photobleaching approach, rapid 
exchange between PLB and SERCA was observed with a time constant of 1.4 s.  With this 
result in combination with our steady-state experiments where Ca2+ decreases PLB-
SERCA FRET, we initially hypothesized that a single Ca2+ transient would cause a small 
but detectable decrease in PLB-SERCA FRET.  To test this hypothesis, we expressed our 
fluorescent PLB and SERCA proteins in paced adult ventricular myocytes and 
simultaneously measured FRET and Ca2+ concentration. 
Characterization Myocyte FRET Detection 
 Myocyte culture and adenoviral infection are discussed earlier in the Materials 
and Methods section.  Localization of YFP-PLB and Cer-SERCA2a was verified with 
confocal microscopy.  Images show adult ventricular myocytes expressing Cer-SERCA2a  
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Figure 19: Adenoviral expression of Cer-SERCA and YFP-PLB in cardiac myocytes.  
Confocal images of an isolated adult rabbit ventricular myocyte expressing Cer-SERCA 
and YFP-PLB. Both proteins were distributed in longitudinal streaks as well as striations. 
The striations were due to localization of both proteins at the Z-line, as indicated by 
counterstaining with the membrane dye FM 4-64. The overlay image shows the relative 
localization of Cer-SERCA, YFP-PLB, andFM4-64. Scale bar = 10 µM. 
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and YFP-PLB displaying a striated pattern of fluorescence as well as longitudinal streaks 
(Fig. 19), suggesting localization in the junctional and transverse SR, respectively.  
Counterstaining with the membrane dye FM 4-64 demonstrate that the t-tubule system 
was largely intact after 2 days of culture.  The overlay image shows that the striated 
pattern of SERCA and PLB corresponds to the Z-lines of the sarcomeres.  By measuring 
fluorescence recovery after photobleaching, our lab has also shown that both PLB and 
SERCA can diffuse across multiple sarcomeres during the course of several minutes 
(Bidwell et al., 2011). 
The protein dependence of FRET between PLB and SERCA in these cells was also 
quantified using the E-FRET method used in the earlier steady-state experiments in AAV-
293 cells and described in the Materials and Methods section.  FRET increased with 
protein concentration towards a maximal value, consistent with the measurements 
discussed previously in AAV-293 cells (Bidwell et al., 2011). 
Single Calcium Transient FRET Measurements 
 Myocytes were infected with Cer-SERCA2a and YFP-PLB and loaded with Ca2+ 
indicator dye as discussed in Materials and Methods and then perfused with PC-1 
medium and stimulated at a rate of .25 Hz.  Confocal time course imaging was 
performed in x-t mode (linescanning) also described in Materials and Methods.  Fig. 20A 
shows the average of 21 con- transients obtained by line-scan mode measurements of 
the indicator X-rhod-1 (black trace) normalized to diastolic Ca2+. We obtained 
simultaneous measurements of YFP and Cer fluorescence with 458 nm excitation. We  
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Figure 20: Quantification of calcium and FRET changes in single transients.  (A) An 
average of 21 consecutive calcium transients quantified by X-rhod-1 fluorescence (black) 
and the corresponding PLB-SERCA FRET ratio (red) in a paced ventricular myocyte.  (B) 5 
µM isoproterenol increased the magnitude and decreased the width of the calcium 
transient. 
A 
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did not detect a systole-to-diastole change in the normalized YFP/Cer ratio (Fig. 20A, red 
trace), suggesting that FRET from Cer-SERCA to YFP-PLB is not abolished during systole.  
The β-adrenergic agonist isoproterenol (5 µM) increased the amplitude and decreased 
the duration of the Ca2+ transient (Fig. 20B), but FRET was still unaffected. 
FRET Response to Pacing 
 Since individual Ca2+ transients were insufficient to produce an observable 
change in PLB-SERCA FRET we hypothesized that FRET would be abolished by a larger 
prolonged elevation of cytosolic Ca2+.  To do so, we alternated between intervals of rest 
(no stimulation) with intervals of 1-Hz pacing producing a rapid and progressive increase 
in average Ca2+.  While not naturally occurring, this protocol shows that our detection 
method is capable of observing real-time changes in PLB-SERCA FRET in response to 
rapid changes in physiological Ca2+ concentration.  Essentially, we use the cellular 
machinery of the myocytes rapidly alter Ca2+ concentration. 
In response to Ca2+ changes of this protocol, we observed a modest reduction in 
the normalized YFP/Cer ratio with rapid pacing apparent in the absence (Fig. 21A) or 
presence (Fig. 21B) of 5 µM isoproterenol.  Fig. 21C/D (black) shows the mean cytosolic 
Ca2+ elevation for control (n = 6 cells) and after the addition of isoproterenol (n = 4 cells) 
normalized to resting Ca2+, and the corresponding mean YFP/Cer ratio is shown in red.  
During pacing intervals, the mean cytosolic Ca2+ was significantly elevated when 
compared with rest, both before (p < 0.01) and after (p < 0.01) isoproterenol.  FRET was 
also significantly decreased when compared with rest, both before (p < 0.05) and after  
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Figure 21: Quantification of calcium and FRET changes by alternating pacing.  (A) 
Prolonged elevations of Ca2+ (black) were achieved with intervals of rapid (1 Hz) pacing 
after periods of rest (no stimulation).  A modest decrease in FRET (red) was observed 
during rapid pacing.  The blue lines represent the Ca2+ and FRET traces smoothed by 5 
second adjacent averaging. (B)  As in A, after 5 µM isoproterenol, a small decrease in 
FRET (red) was observed during rapid pacing.  (C)  Averaging multiple experiments 
showed that rapid pacing increased mean [Ca2+], with a larger increase observed after 
addition of 5 µM isoproterenol. (D) Averaging multiple experiments showed that rapid 
pacing decreased the mean YFP/Cer ratio, and this decrease was larger after addition of 
5 µM isoproterenol.  The first, second, and third pacing intervals are marked “a, b, c.” 
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(p < 0.01) isoproterenol.  Overall, the data are consistent with a small decrease in FRET 
during intervals of rapid pacing. 
FRET Response to Calcium Changes in Heterologous Cells 
 With the time resolution of Fig. 21, we can estimate that the change in FRET 
occurs within 2 seconds of elevation of the Ca2+.  However, this is a much longer than 
the time course of a single Ca2+ transient.  We therefore cannot conclude if the 
rest/pace protocol produced a change in FRET due to a higher Ca2+ concentration, a 
more prolonged Ca2+ elevation, or both. 
 To test these possibilities, we set out to measure the time response of PLB-
SERCA FRET to elevations of Ca2+ in AAV-293.  Cells expressing Cer-SERCA and YFP-PLB 
were loaded with X-Rhod-1 as in the myocytes, and then bathed in PBS containing 1 mM 
EGTA and ionomycin.  Image acquisition of E-FRET and Ca2+ concentration every 10 s 
was started at this low concentration.  After 1 min of acquisition to achieve baseline 
signals, PBS containing 2 mM Ca2+ added and acquisition continued.  Fig. 22 shows that 
increases in Ca2+ concentration appear to directly coincide with decreases in FRET signal, 
suggesting a rapid response.  However, time resolution of this approach is insufficient to 
clearly determine the time course of the Ca2+ action.  Further experimentation with 
faster time resolution is needed, but indicates that this methodology clearly detects 
changes in FRET in response to Ca2+ over time. 
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Figure 22: Time course of calcium effect on PLB-SERCA FRET. In AAV-293 cells bathed in 
10 µM ionophore, addition of 1 mM Ca2+ to the bath solution increases intracellular Ca2+ 
concentrations estimated by average X-Rhod-1 fluorescence (black).  Average PLB-
SERCA FRET (red) decreases rapidly in response to the elevated Ca2+. 
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Summary 
 We observed no change in PLB-SERCA FRET in response to the individual Ca2+ 
transients of paced cardiac myocytes.  Even with the enhancement of these transients 
from the exposure to β-adrenergic stimulation, no change could be observed.  However, 
we did observe a small (2%) decrease in FRET in response to intervals of prolonged rapid 
pacing and rest, which produced relatively higher and more prolonged elevations of 
cytosolic Ca2+ compared to individual transients.  While not a physiologic pacing pattern, 
this protocol demonstrates the capability of our approach in detecting real-time 
changes in FRET in response to physiological changes in Ca2+ concentration.  We must 
now attempt to determine the specific time domain of Ca2+ action on PLB-SERCA FRET. 
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CHAPTER VIII DISCUSSION 
Global versus Single Molecule Effects 
 One of the ultimate goals of this research is to understand the mechanism of PLB 
inhibition of SERCA with respect to how individual molecules interact and function.  
However, our work, as well as the studies that have preceded it, is attempting to do so 
by making global assessments of a large population of molecules.  While we attempt to 
favor the existence of a particular conformation of SERCA in our steady-state 
measurements, we ultimately only achieve an equilibrium shift in a distribution of 
several conformations.  In our real-time FRET measurements, we are not observing 
synchronous changes in all PLB-SERCA interactions, so at any given point in time we are 
observing several interacting states.  Therefore, any given measurement of the PLB-
SERCA interaction is a composite of many interacting molecules from which we attempt 
to deduce information on the interaction of individual molecules.  This is not a critique 
of our approach given the inherent difficulty of making single molecule measurements, 
but merely an important consideration necessary to put our results, and the results of 
others, in the proper perspective. 
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Steady State FRET 
 We have used FRET to measure the interaction between fluorescently tagged 
PLB and SERCA in cells under conditions that favor particular structural conformations of 
SERCA.  At low Ca2+ concentrations that favor the E2 SERCA state, we have observed 
that PLB interacts with SERCA in a protein dependent manner consistent with our 
previous use of this approach (Ha et al., 2011; Hou & Robia, 2010; Hou et al., 2008; Kelly 
et al., 2008; Song et al., 2011).  This observation is also consistent with both the 
Dissociation and Subunit Models of PLB-SERCA regulation, since both predict that PLB 
interacts with the E2 conformation with high affinity.   
When Ca2+ was elevated to saturating concentrations favoring the E1 
conformation, we observed that PLB-SERCA FRET was decreased, but not completely 
abolished (Fig. 13).  The decreased FRET can be explained as a reduced affinity between 
PLB and SERCA (increased KD2) without a change in the structure of the regulatory 
complex (no FRETmax change).  While binding is decreased at any given protein 
concentration, significant levels of binding are detected at saturating concentrations of 
Ca2+.  This is inconsistent with the Dissociation Model where FRET would be predicted to 
be completely abolished.  In theoretical terms, the mutually exclusive binding described 
by the Dissociation Model predicts a KD2 value that approaches infinity with increasing 
Ca2+ concentrations.  KD2 certainly would not achieve a maximal level as we observed.  
Under physiological constraints, an increase in the KD2 value by a few orders of 
magnitude at millimolar Ca2+ would effectively correspond to the Dissociation Model.  
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However, the much lower 40% increase in KD2 would not be consistent with complete 
dissociation of PLB and SERCA at physiological conditions Ca2+ concentrations. 
One might argue detection of PLB-SERCA binding in the presence of Ca2+ is an 
artifact of our approach.  The high concentrations of proteins in the membrane will 
place non-interacting proteins in close enough proximity to undergo energy transfer.  It 
is certainly possible that unbound proteins will undergo FRET.  However, in a 
competition assay using unlabeled PLB, we currently estimate FRET between unbound 
membrane proteins or “non-specific FRET” around at most 4%.  This is clearly much 
lower than the 28% FRET observed with our assay.  Furthermore, we have shown that 
the estimated distance between the probes can be specifically altered  and that this 
distance is consistent with known structure of SERCA(Hou & Robia, 2010; Kelly et al., 
2008; Song et al., 2011). These observations suggest that FRET is not likely caused by 
aggregation of the fluorescent probes which has been suggested to skew FRET 
measurements (Chen et al., 2006). 
These results are more in line with the Subunit Model and the previous FRET 
studies where high levels of PLB-SERCA binding are detected even in the presence of 
Ca2+ (Mueller et al., 2004).  Mueller et al observed only a minimal decrease in FRET in 
the presence of Ca2+ at the highest protein concentrations rather over the full range of 
concentration as was observed with our approach.  This decrease in was consistent with 
a small structure change of the regulatory complex corresponding to approximately a 1 
Å movement that was not detected with our approach.  Unlike our results, Mueller et al 
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did not observe a change in PLB-SERCA affinity, but it is possible that their method did 
not assess interaction at sufficiently low protein concentrations where the affinity effect 
would be observed.  Although we observed no change in our distance measurements, a 
1 Å movement is within the error of our method.  The larger size and rotational mobility 
of the fluorescent proteins used in our method may mask the subtle change Mueller et 
al observed using small, covalently attached fluorophores. 
Just like Ca2+, the presence of the SERCA inhibitor Tg has been shown to 
completely abolish PLB-SERCA crosslinking (Chen et al., 2006, 2005) but only slightly 
diminish FRET in our system.  Like Ca2+, we observed that Tg reduced PLB-SERCA affinity 
(increased KD2) with no change in the structure of the complex (no change in FRETmax) 
(Fig. 15).  While assessing the ability of PLB and SERCA to interact in the presence of Tg 
does not assist in the modeling the PLB-SERCA mechanism, it does aid in the validation 
of our FRET approach.  Because Tg is membrane permeable, its application is a more 
straight forward protocol as compared to Ca2+ which requires saponin permeabilization 
to introduce artificial cytosolic solutions.  Our observation of a lack of complete PLB-
SERCA dissociation at elevated Ca2+ concentrations is likely not due to insufficient 
permeabilization or inappropriate solutions since Tg produced a comparable effect. 
Early proteolysis studies displayed no difference in the fragmentation patterns of 
SERCA at low Ca2+ concentrations and in the presence of Tg (Sagara & Inesi, 1991).  This 
observation was thought to indicate that SERCA bound by Tg was comparable to the E2 
Ca2+ free conformation.  Tg was then used to stabilize SERCA in what was assumed to be 
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the E2 conformation for some of the first high resolution crystallographic studies 
(Danko, Yamasaki, Daiho, Suzuki, & Toyoshima, 2001; Toyoshima & Nomura, 2002).  
However, current consensus suggests that SERCA bound by Tg is not representative of 
the E2 conformation, and alternative crystal structures of the E2 conformation have 
been developed in the absence of Tg.  Our Tg dose response curve (Fig. 15B), showing 
two PLB affinity states, also suggests that SERCA bound by Tg is a structural 
conformation distinct from the E2 Ca2+ free conformation.  We have named this 
conformation “E2-Tg” for its similarity to, yet distinct from, the E2 Ca2+ free 
conformation.  The E2 and E2-Tg conformations likely have similar cytosolic orientation 
exposure the same cleavage sites, yielding the same banding pattern.  They however 
differ greatly in the transmembrane region where the strength of the PLB-SERCA 
interaction is likely dictated. 
Both the Ca2+ and Tg effects on our FRET measurements occur in the same range 
of concentrations as the crosslinking approach.  This similarity suggests that both 
approaches are likely detecting the same change in PLB-SERCA binding, but are just 
detected by a different signal.  This consistency helps validates our overall FRET 
approach showing that the changes we observe are not unique to our system. 
Because of the predicted large structure changes in the cytosolic headpiece 
between the E1 and E2 conformations of SERCA, we thought it likely that this could 
generate a large structural change in cytosolic region of the PLB regulatory complex.  
However, we did not observe a change in the FRETmax parameter, indicating no change 
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in the position of the fluorescent probes attached to the N-terminus of both PLB and 
SERCA, loci that would be thought to move apart.  During the E2 to E1 transition, there 
could be a coordinated movement of both fluorescent probes that does not change the 
distance between them.  On the other hand several studies have suggested that the 
movement of the SERCA headpiece is much smaller than initially predicted (Jensen et 
al., 2006; Sørensen et al., 2004; Winters et al., 2008).  These more subtle changes could 
also explain the lack of a FRETmax change in our experiments 
Under no conditions were we able to detect complete loss of PLB-SERCA FRET.  
In particular, we observed a high degree of FRET between PLB and SERCA under 
conditions that favor particular conformation (E1 and E2-Tg) that have been shown to 
block chemical crosslinking.  These crosslinking observations are the backbone of the 
Dissociation Model.  In contrast, our evidence suggests the high likelihood that PLB can 
bind all conformations of SERCA, although with varying affinities.  This conclusion is 
summarized in Fig. 23 showing the coupled equilibrium between PLB pentamer, 
monomer, and monomer bound to various conformations of SERCA with independent 
dissociation constants. 
While we have not performed an exhaustive investigation into all possible 
conformations, we have observed a high level of FRET even at saturating Ca2+ 
concentrations known to fully relieve PLB inhibition of SERCA.  This suggests that PLB 
can remain bound throughout the reaction cycle SERCA, implying ability to bind all 
conformations.  We therefore conclude that unbinding of PLB is not required for relief  
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Figure 23: Summary of PLB binding.  PLB monomer can bind to itself forming a pentamer 
or bind to SERCA in any conformation, however doing so with varying affinity. 
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of PLB-SERCA inhibition.  This is not without precedence since it phosphorylation of PLB 
has been suggested to relieve inhibition without causing dissociation of the regulatory 
complex. 
Alternative Binding Site 
In our Ca2+ dose curve, we detect two different modes PLB-SERCA binding.  The 
change in binding states could describe a simple structural reorientation merely 
decreasing the strength of the intermolecular contacts of PLB at the same location on 
SERCA.  On the other hand, the detected change could be described by displacement of 
PLB to an alternative binding site.  Crosslinking by the Jones lab (Chen et al., 2007, 2006, 
2005; Jones et al., 2002) and mutagenesis studies by the MacLennan lab (Y Kimura et al., 
1996; MacLennan, Kimura, & Toyofuku, 1998; Toyofuku et al., 1993) provide good 
evidence for a site of interaction that also likely facilitates inhibition.  To this point, there 
has been no direct evidence of an alternative binding site for PLB on SERCA.   
However, some evidence for an alternative site comes from X-ray 
crystallography studies predicting the binding of homologous proteins, NKA and PLM, at 
a more exterior location on helix M9 (Fig. 7) (Shinoda et al., 2009).  While this provides 
sufficient evidence to hypothesize the existence of two distinct PLB binding sites on 
SERCA, it certainly does not confirm it.  This exterior binding site could be unique to the 
PLM-NKA complex and could be the sole site of interaction.  However, it seems unlikely 
that proteins with such similarities would have vastly different interactions and 
inhibitory mechanisms.  The more likely explanation is that this detected interaction is 
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just an artifact of crystallization and does not describe the actual functional site of 
interaction between NKA and PLM. 
One could argue that interaction at the Ca2+ binding site is the only important 
interaction.  The displacement of PLB to an alternative binding site and the complete 
displacement of PLB from SERCA are not significantly different, since both describe a 
movement out of the functional site.  However, this difference would greatly alter the 
dynamics of the system.  Binding of PLB to an alternative site would enhance the on-rate 
of PLB by keeping it in close proximity to the functional site.  In other words, its effective 
concentration would be much higher.   
The Jones group has questioned our proposal of an alternative binding site for 
PLB since their crosslinking studies have found no evidence of a second site (Akin & 
Jones, 2012).  However, they have yet to look for enhancement of crosslinking at an 
exterior site by Ca2+.  Their evidence is the use of crosslinkers varying in distance from 0-
15 Å which have not shown differential binding.  However, movement of PLB by 20 Å 
places it just outside the predicted binding groove and our exterior site corresponds to a 
movement of 40 Å. 
The role of this potential binding site is unclear and could be merely serve as a 
place holder to enhance on and off rates of PLB.  The importance as a place holder 
should not be underestimated, because variations in the ability to bind the alternative 
site will likely have a tremendous impact on how PLB interacts with the functional site.  
Changes at the alternative site would alter the equilibrium binding producing a different 
101 
 
stead-state interaction and inhibition.  Also, there would be a significant impact on the 
dynamics of inhibition since the on and off rates at the functional site could be altered.  
Besides affecting how PLB interacts at the primary functional site, the secondary site 
itself may have the ability to functionally regulate SERCA.  Whatever the purpose of the 
secondary site, the next step of the investigation is determining whether it exists, 
followed by a characterization of the site.  We could then attempt to alter the 
interaction at the secondary site and then determine how the ability of PLB to regulate 
SERCA is changed.  If this secondary site is confirmed to exist, an intriguing question that 
results is how binding at one site excludes binding at the other site, since a strict 
PLB:SERCA stoichiometry of 1:1 is observed. 
Proposed Model of PLB Inhibition 
We have attempted to reconcile the findings of others to account for the 
limitations of all approaches and develop a model that is consistent with all data in the 
field.  We propose that high Ca2+ displaces the transmembrane domain of PLB to an 
alternative, lower affinity binding site on SERCA, with no change in the position of the 
cytosolic domain.  We have termed this the “Domain Displacement Model.”  In other 
words, binding to the E1 and E2 conformations of SERCA differs only in the position and 
affinity of the transmembrane domain of PLB.  This accounts for our data showing that 
Ca2+ reduces the affinity of PLB for SERCA.   This also explains why our data and FRET 
measurements from Mueller et al detect no or only a small change in the position of the 
cytosolic domain where the fluorophores are attached.  Movement of the 
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transmembrane domain to a more exterior site would also explain why Jones sees no 
crosslinking at high Ca2+.  The differences between the models are summarized in Fig. 
24. 
We started to directly test this model by measuring FRET between SERCA and a 
truncated PLB lacking the cytosolic domain which would assess the position of the 
transmembrane domain of PLB in association with SERCA.  Our YFP-tmPLB construct 
expresses normally and interacts with itself and SERCA at low Ca2+ concentrations as 
anticipated.  However, FRET between Cer-SERCA and YFP-tmPLB is unresponsive to Ca2+ 
and does not appear to regulate SERCA.  So while YFP-tmPLB retains some of the 
binding characteristics of full-length PLB, clear differences are apparent.  We suspect 
that steric barriers created by the membrane and SERCA may be preventing proper 
localization, and therefore function, of YFP-tmPLB.  Further experimentation is needed 
to address these results including additional characterization of the YFP-tmPLB 
construct as well as development of alternative constructs.  While this construct did not 
function as initially hypothesized, it does provide evidence for a non-functional PLB-
SERCA interaction.  Assessment of how this interaction occurs without inhibition of 
SERCA could also be critical to our understanding of the PLB-SERCA mechanism. 
Earlier studies showing the ability of truncated PLB to inhibit SERCA were 
performed at a high excess of PLB peptide (Hughes et al., 1996; Y Kimura et al., 1996), 
with no assessment of its interaction or affinity.  The conclusions from these studies that  
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Figure 24: Models of PLB-SERCA binding.  The previously discussed Dissociation and 
Subunit Models are shown in comparison to our proposed Domain Displacement Model.  
We propose that elevated calcium concentration displaces the transmembrane domain 
of PLB to alternative SERCA binding site of lower affinity, with no change in the binding 
location of the cytosolic domain. 
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fully inhibit SERCA may have been incorrect, and even if the suspected steric issues with 
YFP-tmPLB are corrected, full inhibition may not be achieved. 
Effects of Pacing on Myocyte FRET 
 Irrespective of the mechanistic model of inhibition, it is critical to understand 
how the PLB-SERCA interaction changes over time.  Because the ability of PLB to inhibit 
SERCA varies with respect to Ca2+ concentration, the level of PLB inhibition will not be 
constant in cardiac myocytes.  Not only is Ca2+ concentration perpetually changing over 
the course of individual Ca2+ transients; basal concentrations can also be altered by 
various stimuli.  To date however, all measurements of the ability of PLB to bind to and 
regulate SERCA have been taken at equilibrium.  So we have no comprehension of how 
rapidly the PLB-SERCA binding changes in response to changes in Ca2+ concentration.  
Since Ca2+ concentration changes rapidly and constantly in the physiological 
environment of PLB and SERCA, we must assess the dynamics of the PLB-SERCA 
interaction to fully understand its physiologic function.  Unlike previous studies, our 
FRET approach is capable of assessing PLB-SERCA binding in real time.  We are therefore 
uniquely poised to address this critical question. 
 We detected no change in PLB-SERCA FRET over the course of a single Ca2+ 
transient.  Only by using a non-physiological rest/pace protocol that produced higher 
and more sustained Ca2+ increases were we able to observe changes in FRET.  These 
observations were somewhat expected since our steady-state experiments predict at 
most a small 3% change in FRET in response to increases in Ca2+ concentration.  These 
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observations could be explained in a few ways.  It might indicate that there are two 
significant pools of SERCA, PLB unbound (active) and PLB bound (inactive).  This PLB 
unbound and active pool of SERCA is sufficient to move the Ca2+ of a typical single 
transient back into the SR.  Only when Ca2+ concentrations are elevated during our 
rest/pace protocol, and additional SERCA activity is required, is PLB inhibition relieved 
and a decrease in FRET observed.  However, these distinct bound and unbound pools 
are inconsistent with several studies that have suggested that SERCA is nearly 100% 
bound by PLB under basal conditions in larger mammals (Waggoner et al., 2009).  Our 
observed pacing effects are more consistent with the scenario where dissociation of PLB 
from SERCA is not required for the relief of inhibition.  The SERCA activity necessary over 
the course of a Ca2+ transient could then be achieved without a significant change in 
PLB-SERCA interaction.  Only when Ca2+ concentrations are elevated during our 
rest/pace protocol is the PLB-SERCA affinity shifted sufficiently to generate a decrease in 
FRET. 
 Lack of an observable change in FRET does not indicate an absence of change in 
PLB-SERCA binding over the course of a single Ca2+ transient.  Certainly, a change in 
binding can occur that would not significantly alter FRET.  As discussed previously 
concerning an alternative binding site on SERCA, the position of the fluorescent protein 
at the N-terminus of PLB does not allow detection of a change in the position of the 
transmembrane domain.  If applying our proposed Domain Displacement Model of PLB 
interaction (Fig. 24), one could envision that the transmembrane domain of PLB 
106 
 
transitions rapidly between the two binding sites in response to changes in Ca2+, with no 
change in the position of the cytosolic domain.  A YFP-tmPLB that could successfully 
produce the anticipated response to Ca2+ would be a useful tool to investigate potential 
changes in the position of the transmembrane domain in response to Ca2+ transients.  
However, if successful, this type of experiment should be viewed with caution since the 
cytosolic domain could facilitate any transition.  Its absence could certainly then affect 
the rates of transition. 
Future Directions 
 While our proposed model of PLB inhibition of SERCA is a plausible explanation 
that could integrate our data with previously published research, we lack sufficient 
support for this model.  We must first determine whether the secondary site exists and 
whether Ca2+ can cause transition to this binding site.  The FRET experiments with the 
truncated PLB could be capable of showing both, but the initial experiments have not 
produced the anticipated results.  We suspect that steric hindrance of the fluorescent 
protein may be preventing proper localization of tmPLB.  If correct, tmPLB lacking YFP 
should then be able to properly interact and inhibit SERCA.  This could be tested by 
developing an unlabeled peptide consisting of only residues 28-52 of PLB probing the 
ability of this peptide to inhibit SERCA.  If unlabeled tmPLB is not functional, this would 
directly challenge previous observations that the transmembrane domain in isolation is 
fully capable of inhibiting SERCA (Hughes et al., 1996; Y Kimura et al., 1996).  Though 
this seems unlikely since an analogous protein sarcolipin, which lacks a comparable 
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cytosolic domain, is able to inhibit SERCA activity (Bhupathy et al., 2007; Periasamy, 
Bhupathy, & Babu, 2008).   
Also, if FRET between YFP-tmPLB and Cer-SERCA is diminished by expression of 
unlabeled PLB or tmPLB (if functional), this would demonstrate binding competition.  
This would indicate that the YFP-tmPLB interaction with SERCA is not anomalous and 
not an artifact of our approach.  Furthermore, it could indicate that YFP-tmPLB 
preferentially interacts at the secondary, non-inhibitory site. 
 If steric hindrance of YFP is the contributing factor preventing ability of YFP-
tmPLB to inhibit SERCA, modifications to the construct could relieve the steric block.  
Specifically, the 7 amino acid linker between tmPLB and YFP could be lengthened so that 
YFP could be positioned further away from the membrane.  Use of the shortest linker 
that is able to allow proper inhibition of SERCA would be ideal.  This would alleviate 
some potential variability in FRET measurements produced flexibility and movement of 
the fluorescent protein.  In order to be versatile, the additional linker sequence should 
be comprised of simple amino acids such as glycines.  Use of prolines could also be 
considered since they may provide some stability to the linker, thereby reducing 
flexibility and potential variability of FRET measurements. 
 Rather than developing PLB variants to investigate the potential secondary site, 
we could also make modified SERCA proteins.  We could make targeted mutations of 
helix M9, in an attempt to disrupt binding at the proposed secondary site.  Diminished 
binding at the secondary site would be observed as a further lowering of affinity at high 
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Ca2+ concentrations compared to non-mutated SERCA.  Furthermore, if PLB exists in 
equilibrium between the two sites, decreased affinity at the secondary site could 
enhance affinity at the primary functional site presenting as increased affinity at low 
Ca2+ concentrations and enhanced inhibition by PLB. 
 SERCA3 could provide for an interesting model for the investigation of the PLB-
SERCA mechanism.  While PLB has been clearly shown to have no effect on the activity 
of SERCA3 in functional assays (Y Kimura et al., 1996; Toyofuku et al., 1994), the ability 
of PLB to bind SERCA3 has not been determined.   Measuring FRET between YFP-PLB 
and Cer-SERCA3 might provide a unique perspective, potentially showing a non-
inhibitory binding interaction.  Perhaps this interaction would be unresponsive to Ca2+ 
suggesting PLB can only bind the secondary, non-inhibitory site.  
 Our FRET results and proposed model would greatly benefit from support of 
alternative approaches.  While crosslinking results to date have directly contrasted our 
findings, we believe this approach could be modified to show binding at a secondary 
site.  Jones et al have not found evidence of a secondary binding site, but this could be 
attributed to the fact that they have yet to directly test the existence of an alternative 
binding site.  All studies have targeted residues in the suspected binding pocket of 
M2/M4/M6 on SERCA.  Binding at a more exterior position such as M9 would go 
undetected.  Therefore, use of untargeted reagents such as benzophenone and 
glutaraldehyde which bind carbon and amine groups may successfully crosslink PLB to 
SERCA at a position outside the proposed binding pocket under saturating Ca2+ 
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conditions.  Additionally, SERCA mutants could be generated that introduce cysteines or 
lysines on helix M9 to perform so that the site directed crosslinking protocols of the 
Jones lab could be used. 
Concluding Remarks 
 In this dissertation, I have shown our evidence that suggests that dissociation of 
PLB from SERCA is not required for relief of inhibition.  To account for this observation 
as well as previous data from other labs, I have also described the Domain Displacement 
Model of regulation.  Furthermore, I have also demonstrated the ability to detect PLB-
SERCA binding in real-time in response to physiological changes of Ca2+ concentration.  
Doing so, I have shown evidence that single Ca2+ transients of paced cardiac myocytes 
do not produce an observable change in PLB-SERCA binding.  The results and 
methodology presented here have added to our understanding of PLB-SERCA regulation 
and continuation of this research is poised to answer critical questions in the field. 
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